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 Dietary docosahexaenoic acid (22:6n-3, DHA) has been shown to exert beneficial effects 
on coronary heart disease including the prevention of ischemia reperfusion injury. The ability to 
acutely infuse DHA to the heart to prevent ischemia reperfusion injury is a potentialy valuable 
tool in planned surgery where reperfusion and/or ischemia will take place including coronary 
artery bypass surgery and angioplasty.  In the present study, hearts from chow-fed (AIN-93M) 
Sprague Dawley rats (male) 9-12 weeks of age were isolated and artificially perfused.  The 
protocol included: 30 min stabilization period, 30 min global no flow ischemia, 15 min fatty acid 
infusion with reperfusion, and 75 min reperfusion in the absence of fatty acids.  The fatty acid 
infusions included 10, 20, 40, 60, 80, 100 or 120 µM of either palmitate or DHA complexed to 
3% essentially fatty acid free bovine serum albumin as well as a vehicle control. Heart functional 
data was recorded continuously and total heart infarct volume was determined after staining with 
triphenyltetrazolium chloride.  DHA at 10µM significantly reduced the infarction area at the end 
of the reperfusion period compared to that observed in the10µM of palmitate and vehicle control 
conditions. Infarction areas after infusions with DHA or palmitate were similar to controls after 
20-60 µM infusions and greater than controls after 80-120 µM infusions, except for the 100 µM 
palmitate conditions which were similar to the low and high doses.  In this model of infusion, 120 
µM of fatty acid was the maximum amount of DHA tolerated, as several hearts went into 
fibrillation and did not recover and failed to complete the reperfusion at concentrations greater 
than 120 µM of DHA. DHA and palmitate also exerted dose dependent effects on functional 
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The cardiovascular benefits of dietary fish oil were first noted in early 1970‟s as the Inuit 
of Greenland were observed to have a very low rate (3.5%) of death from ischemic heart disease  
relative to Western populations despite a significantly higher intake of meat and fat and lower 
intakes of fruits and vegetables (Bang, Dyerberg, & Nielson, 1971). Due to the landscape of 
northern Greenland, the natives are mostly hunters and fishermen, eating mostly meat of whales, 
seals/walrus, and fish. Meat from marine origin is very high in omega-3 polyunsaturated fatty 
acids (PUFA), specifically the long-chain omega-3 PUFA, or omega-3 highly unsaturated fatty 
acids (HUFA, ≥20 carbons, ≥3 carbon-carbon double bonds). After analyzing the diet of the 
Greenland Inuit, it was found that their diet consisted of approximately half the amount of 
omega-6 fatty acids and almost 5 times the amount of omega-3 fatty acids compared with Danish 
controls. Their serum lipid profiles reflected this; omega-6 HUFA were replaced largely by 
omega-3 HUFA (Bang, Dyerberg, & Sinclair, 1980).   
One of the main benefits of dietary fish oils on coronary heart disease is an antiarrhythmic 
effect that was first noticed in the GISSI-Prevenzione trial (Valagussa et al., 1999). This was a 
large, prospective, randomized controlled trial in which fish oil therapy reduced sudden cardiac 
death (death within 1 hour of symptoms of an acute MI attributed to sustained ventricular 
arrhythmias) 45% compared to controls (P < .001) (Valagussa et al., 1999).  Risk of sudden 
cardiac death has also been shown to be inversely related to base-line blood levels of 
eicosapentaenoic acid (EPA) and docosahexaenoic Acid (DHA) in men without evidence of prior 
cardiovascular disease (Albert et al., 2002).  
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The antiarrhythmic effect of dietary fish oil has also been demonstrated in animal studies. 
This includes dietary intervention studies, where rats fed a diet supplemented with tuna fish oil 
significantly reduced the incidence and severity of arrhythmias, preventing ventricular fibrillation 
during both occlusion and reperfusion and that feeding rats saturated fatty acids from sheep fat 
(high in saturated fats) significantly increased the severity of arrhythmias  (McLennan, 
Abeywardena, & Charnock, 1988). Acute infusion with n-3 HUFA has also produced 
antiarrhythmic results.  In a highly reliable surgically induced ischemia model of sudden cardiac 
death in canines, infusion with a fish oil emulsion prevented the occlusion that typically followed 
arrhythmia in untreated animals or animals treated with a soybean based infusion. (Billman, 
Hallaq, & Leaf, 1994; Billman, Kang, & Leaf, 1997).  These results were reproduced using pure 
infusions of EPA and DHA (Billman, Kang, & Leaf, 1999). 
 Ischemia reperfusion injury is a major determinant of infarct size. Infarcted myocardium 
causes fatal ventricular arrhythmias (Zeghichi-Hamri et al., 2010). Previous dietary studies have 
been conducted to examine the effect of omega 3 highly unsaturated fatty acids on protection 
from ischemia reperfusion injury. A few studies have used an isolated perfused (Langendorff) 
heart model to examine the effects of omega 3 fatty acids in the absence of any neuronal or 
hormonal factors and have reported conflicting results. It has been shown that diets high in n-3 
HUFA (and low in saturated and n-6 fatty acids) reduce (Zeghichi-Hamri et al., 2010; 
Abdukeyum, Owen, & McLennan, 2008) or have no effect (Force et al., 1989) on myocardial 
infarct size in rats. This effect may have been caused by the reduction of other dietary fatty acids 
and not just the increase in omega 3 HUFA or the effect of the diets on other organs. Generally, 
DHA was incorporated into the hearts as phospholipids (Zeghichi-Hamri et al., 2010) which were 
likely released by a variable amount by phospholipases whose activities are increased during 
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ischemia (Ford, Hazen, Saffitz, & Gross, 1991).  To the best of our knowledge no study has been 
conducted examining the affects of an acute infusion of DHA on ischemia reperfusion injury. 
Therefore, the purpose of the present study is to examine the effect of an acute infusion of DHA 
in a model of ischemia reperfusion. The ability to acutely infuse DHA to the heart to prevent 
ischemia reperfusion injury would be an extremely valuable tool in planned surgery where 
reperfusion and/or ischemia will take place including coronary artery bypass surgery and 
angioplasty.  
1.2 Biochemical and Physiological Foundations 
1.2.1 Anti-arrhythmic Effects of Omega-3 HUFA 
Antiarrhythmic effects as well as enhanced postischemic recovery of heart function have 
been shown for dietary fish oil in several animal studies (see Table 1).  The mechanism by which 
free HUFA slows the contractions of cardiomyocytes and prevents arrhythmias is not fully 
known, however it is likely a result of their effects on the electrophysiology of cardiomyocytes 
(Kang & Leaf, 1995). N-3 HUFA act on ion channels to hyperpolarize membrane resting 
potential, increase the action potential threshold, and reduce membrane electrical excitability by 
significantly raising the threshold of depolarizing current required to initiate an action potential. 
Myocytes on the border of an ischemic zone have comparatively depolarized resting membrane 
potentials and probably trigger fibrillation because they are easily excited (Xiao et al., 2008). In 
addition, n-3 HUFA prolong the refractory period and decrease action potential duration. This is 




 and voltage gated Ca
2+
 currents. Activation/opening of Na
+
 
channels allows a rapid influx of sodium ions which leads to the initiation of action potentials. 
The cardiac Na
+
 channel is comprised of a large α-subunit and a smaller β1-subunit. It is 
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speculated that the α-subunit has a specific binding site for n-3 HUFA. EPA and DHA binding to 
the Na
+
 channel accelerates the transition from the resting state to the inactivated state. This 
prolongs the recovery time from inactivation (Xiao, Sigg, & Leaf, 2005).  
Voltage gated L-type Ca
2+ 




release from the 
sarcoplasmic reticulum. An overload of Ca
2+ 
in the cytosol can cause cardiac arrhythmias, so 
prevention of this overload would be antiarrhythmic. The free fatty acid form of n-3 HUFA is 
antiarrhythmic during Ca
2+
 overload in isolated cultured neonatal rat cardiac myocytes (Kang & 
Leaf, 1994). EPA prevents fibrillations when added before Ca
2+ 
induction and EPA terminates 
fibrillations when added after induction. Treatment with bovine serum albumin (BSA), which 
extracts non-esterified fatty acids, re-establishes the induced contractures and fibrillations (Kang 
& Leaf, 1994). This finding suggests that incorporation of the fatty acids into the membrane 
phospholipid is not required for their action. BSA mediated extraction would not be possible if 
the fatty acids had been incorporated into phospholipids or if any other covalent or ionic bonding 
had occurred (Leaf, Xiao, Kang, & Billman, 2003). The direct action of the n-3 HUFA is the 
blockade of the voltage-gated L-type Ca
2+
 current which reduces Ca
2+
 entry. Only the free fatty 
acid form of the HUFA with a free carboxyl group was able to block cardiac Ca
2+
, suggesting 
that it might be interacting with the positively charged amino acids of the channels by 
noncompetitive inhibition, prolonging the inactivated state (Xiao, Gomez, Morgan, Lederer, & 
Leaf, 1997) (Xiao, Wright, Wang, Morgan, & Leaf, 2000). 
In heart, voltage-gated K
+
 channels determine the resting potential, shape, and length of 
the action potential, thus controlling cardiac performance (Honore, Barhanin, Attali, Lesage, & 
Lazdunski, 1994). It has been demonstrated that DHA blocks the major voltage dependent K
+
 
channel (Kv1.5) in cardiac cells. Inhibition of the Kv1.5 channel activity by HUFA is similar to 
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that produced by class 3 antiarrhythmic agents and is also expected to be beneficial during 
ischemia when extracellular accumulation of K
+
 occurs. Blockage of Kv1.5 resulted in inhibition 
of the delayed rectifier current (IK) and the transient outward current (Ito), the two main outward 
K
+ 
currents (Honore et al., 1994; Xiao et al., 2005). The inward rectifying current (IK1),which is 
the main inward K
+
 current, was unchanged by n-3 HUFA (Xiao et al., 2005). MUFA‟s and 
saturated fatty acids which are not antiarrhythmic exert no effects on the major K
+
 currents (Xiao 
et al., 2005). N-3 HUFA assist in stabilizing the increased excitability of partially depolarized 
cells and in doing so prevent arrhythmias (Xiao et al., 2008).  
It has been demonstrated that n-3 HUFA in the phospholipid pool have no antiarrhythmic 
effect (Weylandt, Kang, & Leaf, 1996), but they are available to perform their antiarrhythmic 
action after release by phospholipases, specifically phospholipase A2 which acts to release fatty 
acids (commonly n-3 HUFA) from their sn-2 position. Phospholipase A2 is rapidly activated by 
catecholamines as with a myocardial infarction (MI) (by activation of the sympathetic 
innervation in the heart) as well as during ischemia (Ford et al., 1991). After release, the free fatty 
acids are available to exert their antiarrhythmic effects. During a period of increased n-3 HUFA 
intake, the phospholipid content of EPA and DHA increases (Charnock, Abeywardena, & 
McLennan, 1986). This increases the availability of DHA to be released from phospholipids to 
act on ion channels. In addition, the incorporation of HUFA into membranes increases membrane 
fluidity which may indirectly affect the activity of sarcolemmal proteins including ion channels 




Table 1. Dietary fatty acids and ischemia reperfusion studies. 
Authors Sex and type 
subjects 












TFO (10), SF (11), 
SSO (11) 
15/15 Dietary tuna FO diet significantly reduced the 
incidence and severity of arrhythmias, preventing 




Male, wistar Langendorff 8 wks (10) SSO, (10) 
FO 
20/50 Dietary FO improves the recovery of the cardiac 









12 wk on SSO (25), 




Dietary replacement of saturated fats by n-6 and 
especially n-3 PUFA but not MUFAs can reduce 
the likelihood of an ischemic event leading to 
SCD. 
(Abdukeyum 
et al., 2008) 
Male, Wistar IPC vs. diet  
30 min ischemia and 
120 reperfusion 
6 weeks on FO, SSO, 
or SFA (54) 
30/120 Dietary FO induces a form of preconditioning. 










testing to determine 
arrhythmia 
vulnerability.  
16 week, OO (25), 
SFA (24), SSO (25), 
FO (24) 
15/30 Dietary replacement of saturated fats by n-6 and 
especially n-3 PUFA but not MUFAs can reduce 









testing in Langendorff 
perfused hearts. 
16 wk Low fat (20), 
SFA (10), FO (10) 
15/10 Dietary FO prevented VF in reperfusion after 
ischemia and elevated the current required to elicit 
VF during a programmed ventricular stimulation 
protocol under control or ischemic conditions.  
When arrhythmias occurred in the hearts from fish 
oil-fed animals following any stimulus, the hearts 
always rapidly and spontaneously reverted to 
sinus rhythm 
(Zeghichi-




Occlusion of left 
coronary artery 
8 week, SFA, n-6, 
and n-3 (42) 
30/120 Improved myocardial resistance to ischemia-
reperfusion  
FO, fish oil; OO, olive oil; SSO, sunflower seed oil; SFA, saturated fatty acids; IPC, ischemic preconditioning; MUFA, monounsaturated fatty 
acids; SCD,sudden cardiac death; VF, ventricular fibrillation 
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1.2.2 Ischemia Reperfusion Injury 
Ischemia is a lack of blood flow which causes an imbalance between the demand for 
oxygen and substrates, and their delivery through blood, leading to anaerobic metabolism and 
decreased contractile function (Verdouw, van den Doel, de Zeeuw, & Duncker, 1997).  Ischemia 





 ATPase activity is decreased and the intracellular levels of Na
+
 rise. 
The sodium hydrogen exchanger (NHE) tries to correct the increased H
+
 levels and in doing so 
increases the influx of Na
+
 ions. High intracellular levels of Na
+





 exchanger and increases Ca
2+
 influx and subsequently Ca
2+ 
intracellular levels. Calcium 
reuptake by sarcoplasmic reticulum Ca
2+
-ATPase, is reduced further contributing to an overload 
of calcium ions due to energy depletion (Carmeliet, 1999).  
Reperfusion of coronary flow can save ischemic tissue and restore overall heart function. 
Reperfusion can also paradoxically induce contracture, cellular injury and death (Piper, Meuter, 
& Schafer, 2003). While reperfusion injury and ischemic injury are distinct, they share common 
pathways (Table 2) including, the production of reactive oxygen species (ROS), intracellular 
calcium overload and endothelial dysfunction (Verma et al., 2002). Excessive levels of ROS lead 
to damage of proteins and lipids and can induce apoptosis (Diep, Intengan, & Schiffrin, 2000).  
 
Table 2. Summary of the mechanisms of ischemia reperfusion injury.   
Ischemia Reperfusion 
Oxidative Stress Oxidative Stress 
Intracellular calcium overload Intracellular calcium overload 
Endothelial dysfunction Endothelial dysfunction 
ATP depletion Restoration of pH 
Tissue acidosis Opening of the MPTP 




Calcium overload in cytosol is very damaging to cardiac cells and causes cardiac 
arrhythmias and contracture (ter Keurs et al., 2001). An overload leads to cell damage by 
activating phospholipases (Carmeliet, 1999) and opening of the mitochondrial permeability 
transition pore (MPTP). MPTP is a protein complex spanning both inner and outer mitochondrial 
membranes. It is made up of the voltage anion channel (VDAC) in the outer membrane, the 
adenine nucleotide translocase (ANT) in the inner mitochondrial membrane and cyclophilin-D in 
the matrix. Under physiological conditions it is closed (Lavi & Lavi, 2011). Opening of this pore 
occurs during high levels of intracellular Ca
2+ 
as well as depletion of adenine nucleotides and 
allows the release mitochondrial calcium and apoptotic inducing factors including Cytochrome-C 
(a caspase activator) and Smac/DIABLO (a caspase co-activator) (Zamzami & Kroemer, 2001). 
MPTP opening is inhibited by a low pH, correction of ischemia induced acidosis during 
reperfusion allows MPTP to open. This causes the pore to open mainly in reperfusion and less 
often during ischemia (Halestrap, Clarke, & Javadov, 2004) contributing to reperfusion injury.  
Cytochrome c loss results in uncoupling of the mitochondrial respiratory chain and a decrease in 
ATP synthesis (Zamzami & Kroemer, 2001). Cytochrome C binds to the cystolic protein Apaf-1 
which causes activation of caspase 3 and 9 (Adrain & Martin, 2001). Smac/DIABLO indirectly 
activates Caspase 3 and 9 by sequestering caspase-inhibitory proteins (Zamzami & Kroemer, 
2001). Pro-apoptotic and anti-apoptotic regulating proteins such as the Bcl-2 family of proteins 
can affect the MPTP by promoting either its opening or closure by associating with the 
components of the mitochondrial pore. Bcl-2 and Bcl-xl are anti-apoptotic and conversely, Bad, 
Bid, Bim, and Bax are pro-apoptotic (Gross, McDonnell, & Korsmeyer, 1999).  
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1.2.3 Reperfusion and Omega-3 HUFA 
Reperfusion injury contributes to the ventricular arrhythmia and ischemic death (Bolli & 
Marban, 1999) therefore prevention of this is of upmost importance. DHA appears to play a role 
in the prevention of reperfusion injury. Dietary DHA supplementation delays Ca
2+
 induced 
MPTP opening (Khairallah et al., 2010), but more studies are needed. The ability to acutely 
infuse DHA to the heart to prevent ischemia reperfusion injury would be an extremely valuable 
tool in planned surgery where reperfusion and/or ischemia will take place including coronary 
artery bypass surgery and angioplasty. Therefore, the purpose of the present study is to examine 
the effect of an acute infusion of DHA to a model of ischemia reperfusion. 
1.2.4 Ischemia, Preconditioning and Cardioprotective Agents 
Following periods of ischemia and subsequent reperfusion, the heart often experiences an 
episode of reversible prolonged postischemic contractile dysfunction known as stunning (Kloner 
& Jennings, 2001b). Depending on the degree and duration of the initial ischemic insult, this can 
last from hours to weeks (Bolli & Marban, 1999). The mechanism of stunning is complex and not 
fully known, however it appears that it involves oxygen derived free radicals generated during 
reperfusion as well as an alteration in calcium homeostasis (Bolli & Marban, 1999). Evidence for 
this comes from experimental studies showing that oxygen radical scavengers and calcium 
channel blockers enhance function of stunned myocardium (Kloner & Jennings, 2001a). Brief 
periods of ischemia (≤15 minutes) can contribute to prolonged left ventricular dysfunction, but 
they can also have a cardioprotective role. Brief episodes of ischemia followed by reperfusion 
have been shown to protect the heart from extensive necrosis during subsequent longer periods of 
ischemia, and this phenomenon is termed ischemic preconditioning. Preconditioning is the 
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exposure to a nonlethal stimulus activating the natural endogenous cellular stress response to 
protect against a subsequent more lethal injury. Ischemic preconditioning was first shown by 
Murry at al. in 1986 using a canine model. These authors found that 4 bouts of 5 min cycles of 
ischemia with reperfusion protected the heart from a subsequent episode of ischemia (40 min) 
and reduced infarct size up to 75%.  Following these brief periods of sub lethal ischemia, the 
heart quickly adapted itself to a phenotype that was more resistant to infarction (Murry, Jennings, 
& Reimer, 1986). Ischemic preconditioning markedly reduces arrhythmias during both ischemia 
and reperfusion, and also completely eliminates ventricular fibrillation (Hagar, Hale, & Kloner, 
1991).  Preconditioning also delays the onset of necrosis and preserves levels of high-energy 
phosphate intermediates (Hagar et al., 1991).  
Ischemic preconditioning demonstrates a biphasic pattern with an “early phase” which 
starts within a few minutes of the preconditioning stage and lasts up to 3 hours, and a “late 
phase” which begins 12-24 hours following preconditioning and lasts 2-4 days (Marber, 
Latchman, Walker, & Yellon, 1993).  The mechanism of ischemic preconditioning is not well 
understood, however, it appears that adenosine, opioids, low doses of reactive oxygen species 
(ROS), tumour necrosis factor alpha (TNF-α), bradykinins and prostaglandins that are released 
during ischemia may play a role. These signals activate G-protein-coupled receptors and initiate a 
signaling cascade mediated largely by protein kinase C (PKC) (Das & Das, 2008).  During a time 
of negative energy balance such as during ischemia, adenosine is free to move into the interstitial 
space where it can associate with adenosine receptors. Two of the four subtypes of this receptor, 
A1 and A3, have been implicated as triggers of the preconditioned state (Liu et al., 1994). This 
binding of adenosine to its receptors activates protein kinase C (PKC), specifically the ε isoform 
(PKCε), which has been implicated as the isoform responsible for ischemic preconditioning (Liu, 
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Cohen, Mochly-Rosen, & Downey, 1999). PKCε triggers a cascade of events that are not fully 
understood (Lavi & Lavi, 2011).  
While the early phase is caused by quick signaling cascades using existing proteins, the 
late phase involves synthesis of new proteins. Ischemic preconditioning induces transcription of 
proteins shown to be cardioprotective mediators such as iNOS, COX-2 and heat shock proteins 
(HSP), and their expression coincides with the “late phase” of preconditioning (Valen, 2003). 
Increased HSP expression in rats through in vivo heat exposure has been demonstrated to provide 
a protective effect against ischemia ex vivo with induced ischemia with a Langendorff model 
(Currie, Karmazyn, Kloc, & Mailer, 1988).  In particular, focus has been on HSP 70, which has 
two isoforms; the constitutive HSP70c (HSP73) and the inducible HSP70i (HSP72) (Latchman, 
2001). HSP72 is the predominant isoform involved in protection from ischemia reperfusion 
injury. HSP inhibits apoptosis, decreases cytokine production and decreases activation of the pro-
apoptotic JNK pathway (Latchman, 2001). 
1.2.5  Preconditioning and Omega-3 HUFA 
A preconditioning effect has also been shown for dietary n-3 HUFA (Abdukeyum et al., 
2008). For 6 weeks, male Wistar rats were fed a diet containing either DHA and olive oil (n-3 
PUFA), sunflower seed oil and olive oil (n-6 PUFA), or beef tallow and olive oil (saturated). 
Hearts from rats fed the n-3 PUFA diet had significantly lowered heart rate, end diastolic 
pressure and ischemic and reperfusion arrhythmias. Most importantly these hearts had a smaller 
infarct size compared to both n-6 and saturated fat dietary groups. This nutritional 
preconditioning effect was as powerful as the ischemic preconditioning effect seen in the n-6 
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PUFA and saturated fat groups.  In addition, sub maximal ischemia preconditioning provided a 
benefit for n-6 PUFA and saturated groups, but no additional benefits for the n-3 PUFA group. 
In an acute study, rabbits were pretreated for 4 days over 4 hours with a lipid emulsion 
containing both EPA and DHA at a dose of 5 ml/kg prior to an in situ 30 minute ischemic insult 
followed by 3 hours of reperfusion. This produced a 40% reduction in infarct size (p<0.01) 
compared to controls receiving 0.9% saline infusions and a 225% increase in heat shock protein 
72 (HSP72) levels (p<0.02) (McGuinness, Neilan, Sharkasi, Bouchier-Hayes, & Redmond, 
2006). HSP72 induction is used as a marker of preconditioning because a direct correlation 
between the amount of HSP72 induced and the degree of myocardial protection has been found 
(Hutter, Sievers, Barbosa, & Wolfe, 1994). 
The term preconditioning is loosely defined and the difference between a preconditioning 
agent and a cardioprotective agent is unclear. With preconditioning, a nonlethal stimulus 
activates the natural endogenous cellular stress response to protect against a subsequent more 
lethal injury. It may be possible that n-3 HUFA act as both a preconditioning and a 
cardioprotective agent. Observations of increased heat shock proteins and a reduced infarct size 
implies that DHA infusions may provide an initial insult to the myocardium which upregulates 
protective preconditioning mechanisms (McGuinness et al., 2006). Alternatively, studies 
demonstrating a benefit of acute infusion of pure DHA and EPA (Kang & Leaf, 1994; Kang & 
Leaf, 1995; Kang & Leaf, 1996; Xiao et al., 2008) provide the argument that n-3 HUFA act as a 
direct cardioprotective agent. 
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1.2.6 Fatty Acid Uptake and Oxidation 
Short Chain (≤6 carbons) and medium chain (8-12 carbons) fatty acids are transported via 
simple diffusion or “flip-flop”. Long chain (14-22 carbons) and very long chain fatty acids (>22 
carbons) may require additional steps in their movement across muscle plasma and mitochondrial 
membranes.  Long chain fatty acids cross membranes with the assistance of fatty acid transporter 
(Mahadeva & Sauer, 1971). These fatty acid transporters include the integral membrane protein 
fatty acid translocase (FAT/CD-36), the peripheral membrane protein plasma membrane 
associated fatty acid binding protein (FABPpm), heart specific cytoplasmic fatty acid binding 
protein (H-FABP), and fatty acid transport proteins (FATP1 and FATP6). These transporters are 
all present in heart and located at the sarcolemma (Luiken, Turcotte, & Bonen, 1999; Luiken, 
vanNieuwenhoven, America, Vandervusse, & Glatz, 1997; Abumrad, Park, & Park, 1984; Luiken 
et al., 1997). The rate of uptake is governed by the rate of subsequent metabolic reactions inside 
the cell (Degrella & Light, 1980). A trans-sarcolemmal rate of uptake of 65 to 85 nmol/ gram of 
wet weight of myocardial tissue in 1 minute has been reported (Musters, Bassingthwaighte, Van 
Riel, & van der Vusse, 2006). 
The heart is a metabolic omnivore with the capacity to oxidize fatty acids, carbohydrates, 
lactate, ketone bodies and even amino acids. Glucose is rapidly phosphorylated and is either 
incorporated into glycogen or catabolised (Schwenk, Luiken, Bonen, & Glatz, 2008). Long chain 
fatty acids (12-18 carbons and varying degrees of unsaturation) are a major fuel source of the 
heart, with fatty acid oxidation normally providing 60-70% of the hearts energy requirements 
(Bing, 1965; Neely & Morgan, 1974). These levels can be changed based on the availability of 
substrates. Because there is limited capacity for lipid storage in cardiac myocytes, the uptake and 
oxidation of fatty acids need to be tightly coupled (Chabowski, Gorski, Calles-Escandon, 
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Tandon, & Bonen, 2006). The β-oxidation of fatty acids is under complex dynamic control which 
depends on a number of factors, including fatty acid supply to the heart; structure and saturation 
of the fatty acid being supplied, endogenous supplies; the presence of competing energy 
substrates (glucose, lactate, ketones, amino acids); hormonal and neuronal control; energy 
demand of the heart; oxygen supply; fatty acid uptake and esterification; mitochondrial transport 
and drugs (Lopaschuk, Ussher, Folmes, Jaswal, & Stanley, 2010). Existing double bonds of 
unsaturated fatty acids commonly need to be relocated by an isomerase to allow for a required 
dehydration reaction to occur before β-oxidation can begin (Christie, 1989). Very long-chain 
fatty acids (>22carbons) cannot directly enter the mitochondria. Their long hydrocarbon chain 
must first be shortened to only 18 carbons by peroxisomal β-oxidation (Reddy & Hashimoto, 
2001). 
1.2.7 Oxidation during Ischemia 
During periods of limited oxygen supply in the heart, both fatty acid and carbohydrate 
oxidation decrease and ATP production is impaired as oxidative phosphorylation is limited. In an 
attempt to compensate for the decrease in ATP supply, glycolysis and glycogenolysis initially 
increase but become uncoupled from oxidative phosphorylation. The shift from aerobic or 
mitochondrial metabolism to anaerobic glycolysis occurs after only 8 seconds of reduced arterial 
flow to the heart. The shift occurs as soon as the O2 trapped in the tissue as oxyhemoglobin and 
oxymyoglobin is consumed (Jennings, Murry, Steenbergen, & Reimer, 1990). As oxygen 
becomes scarcer, mitochondrial electron transport must decrease. The cycling of acetyl 
intermediaries declines leading to a rise in the acetyl-CoA/CoA ratio. This results in a decrease in 







and lactate climb (Saddik & Lopaschuk, 1991) and fatty acids are diverted from β-oxidation into 
the myocardial lipids depots (Moore, Radloff, Hull, & Sweeley, 1980; Vandervusse, Roemen, 
Prinzen, Coumans, & Reneman, 1982). At this time cell-to-cell electrical uncoupling occurs with 
the onset of ischemic contracture (stiffening of the myocardium), ECG changes appear and 
cystolic Ca
2+
 increases significantly. Contracture, which is marked by a distinct rise in left 
ventricular end diastolic pressure, occurs by an absence of ATP and an overload of calcium in the 
myocyte causing actin-myosin crossbridges to remain in an attached state (Piper et al., 2003). 
Ischemic contracture makes cardiomyocytes more fragile and susceptible to mechanical damage. 
Late in the reversible phase of ischemia up to 80% of the ATP present at the onset of ischemia 
has disappeared. Reperfusion and oxidative flux may occur before permanent damage occurs to 
the myocardium, but the control of fatty acid and glucose oxidation remains impaired (Jennings, 
Schaper, Hill, Steenbergen, & Reimer, 1985).  
During reperfusion of the reversibly injured heart, the predominant source of ATP 
production is fatty acid oxidation (Saddik & Lopaschuk, 1991). These high rates of fatty acid 
oxidation exert detrimental effects on functional recovery of hearts following ischemia 
(Lopaschuk, Wall, Olley, & Davies, 1988) and contribute to contractile dysfunction or “stunning” 
by markedly inhibiting glucose oxidation rates (Kantor, Dyck, & Lopaschuk, 1999; Lopaschuk, 
Wambolt, & Barr, 1993), and by increasing myocardial oxygen consumption (Oram, Bennetch, 
& Neely, 1973). This alteration in energy utilization may be partly caused by substrate supply to 
the heart during reperfusion. In a clinical setting, elevated plasma concentrations of fatty acids 
occur either after acute myocardial infarction or cardiac bypass surgery (Kurien & Oliver, 1966). 
In the presence of high circulating levels of fatty acids, oxidation of fatty acids increases and 
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accounts for almost all of the myocardial ATP production (Bing, 1965; Neely & Morgan, 1974), 
while concurrently suppressing glucose oxidation (Randle, Garland, Newsholme, & Hales, 1963).  
Another possible cause of this shift in metabolism is the dramatic decrease in malonyl-
CoA levels (Kantor et al., 1999). During ischemia AMPK is activated by an accumulation of 
AMP, resulting in phosphorylation and inactivation of ACC during reperfusion, causing the 
observed decrease in malonyl-CoA levels. This accelerates fatty acid oxidation rates by a 
decreased inhibition of CPT-1 (Kudo, Barr, Barr, Desai, & Lopaschuk, 1995).  
1.2.8 Phospholipid Remodeling and Eicosanoid Synthesis 
Glycerophospholipids are important structural and functional components of biological 
membranes and also play important roles as precursors of lipid mediators such as eicosanoids 
(Shimizu, Ohto, & Kita, 2006). Phospholipids are formed through the Kennedy pathway (de novo 
pathway) (Kennedy, 1961), and rapidly remodeled through the Land‟s cycle (Lands, 1958). They 
contain a diacylglycerol (DAG) phosphatidic acid backbone and a spectrum of potential fatty 
acids. EPA, DHA, arachidonic acid (AA) and other HUFA compete with each other to become 
incorporated in membranes at the sn-2-position (Shindou & Shimizu, 2009). Saturated and 
monounsaturated fatty acids are commonly esterfied at the sn-1-position (Shindou & Shimizu, 
2009).  
During de novo phospholipid synthesis, glycerol-3-phosphate (G3P) is acylated with a 
long-chain fatty acid from fatty acyl-CoA to form lysophosphatidic acid (LPA). LPA is then 
acylated (with usually an unsaturated fatty acid) to form phosphatidic acid (PA) (Shindou & 
Shimizu, 2009).  PA is converted to DAG or cytidine diphospho-DAG (CDP-DAG) by a 
cytosolic phosphatase. DAG is converted into either triacylglycerols or phosphatidylcholine (PC) 
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and phosphatidylethanolamine (PE). Phosphatidylserine (PS) can later be synthesized from PC or 
synthesized from CDP-DAG along with phosphatidylglycerol (PG), diphosphatidylglycerol (CL, 
Cardiolipin) and phosphatidylinositol (PI) (Shindou & Shimizu, 2009).  
HUFA such as DHA, are incorporated into phospholipids after de novo synthesis through 
the remodeling pathway (Lands, 2000). AA is the primary fatty acid which becomes esterfied in 
phospholipids with a more minor contribution by other PUFA including DHA. The proportions 
can be altered by the fatty acid composition of the diet (Yamashita, Sugiura, & Waku, 1997).  
The remodeling pathway (or Lands‟ cycle) uses concerted activation of phospholipase A2 (PLA2) 
and lysophospholipid acyltransferases (LPLATs) to alter the fatty acyl composition of 
phospholipid.  PLA2 liberate fatty acids from phospholipids creating lysophospholipids. LPLATs 
work in the opposite direction converting fatty acyl-CoAs and lysophospholipids to 
phospholipids. Phospholipase activation to release fatty acids is also critical for various cell 
signaling and transduction pathways.  HUFA such as AA, EPA and DHA are converted to 
various eicosanoids and docosanoids that act as potent local hormones (Hishikawa et al., 2008).  
Global ischemia dramatically increases phospholipase activity (Ford et al., 1991). The 
enzymes Cyclooxygenase (COX) and lipoxygenase (LOX) are able to produce n-2 series 
eicosanoids from AA. These n-2 series eicosanoids exert strong inflammatory and 
vasoconsrictive effects.  When using EPA and DHA as substrates these enzymes create n-3 series 
prostaglandins and thromboxanes, and 5-series leukotrienes which exert less vasoconstricting and 
inflammatory effects (Lands et al., 1992). In addition, the LOX pathways can also create 
Resolvins and Protectins from DHA. These chemical mediators have potent anti inflammatory 
effects, which have the potential to play a role in atherosclerosis (Ariel & Serhan, 2007). These n-
3 HUFA derived mediators are likely contributing to the cardioprotection by n-3 HUFA in 
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dietary studies. An increase of DHA and ALA in the diet is able to increase the amount of DHA 
in phospholipids (Lands et al., 1992). Any increases in the phospholipid content of DHA would 
increase the amount being released during ischemia and would therefore increase the substrate 
amount for the creation of n-3 series eicosanoids (Abeywardena & Head, 2001) as well as 
resolvins and protectins (Calder, 2007). In addition, increased DHA in the phospholipid pools 
would mean less n-6 HUFA for use as substrates (Calder, 2007). 
The role of eicosanoids and docosanoids in myocadial ischemia reperfusion injury is 
unclear as they appear to exert both beneficial and harmful effects. Prostacyclin (PGl2), a major 
prostaglandin produced in the heart during ischemia and reperfusion, may have protective 
vasodilatation effects. Thromboxanes (TXA2), are potent vasoconstrictors, and contribute to 
infarction and arrhythmias during ischemia and reperfusion (Bouchard & Lamontagne, 1999). 
PD1, a DHA derived protectin has powerful anti-apoptotic effects (Hersberger, 2010). Despite 
the important role that eicosanoids and docosanoids play in ischemia reperfusion injury, studies 
on their effects on heart are lacking. 
1.2.9 N-3 HUFA and Apoptosis 
DHA can induce apoptosis through an increased production of reactive oxygen species 
(ROS) and caspase-3 activity (Diep et al., 2000; Feng, Chen, Lin, & Yang, 2011). In monocytic 
leukemia U937 cells, DHA stimulates phospholipase C (PLC) which hydrolyzes the 
phosphatidylinositol 4,5-bisphosphate in membranes releasing free Inositol Trisphosphate (IP3) 
and diacylglycerol (DAG). Production of these second messengers results in a rapid release of 
Ca
2+
 from the endoplasmic reticulum. PKCγ, a Ca
2+
 and DAG dependent isoform and PKCδ, a 





 channels at the plasma membrane facilitating an increased influx of Ca
2+
 across the 
plasma membrane. Increased intracellular calcium concentrations as well as the activation of 
PKCγ and PKCδ can lead to ROS production from the mitochondria and downstream signaling 
resulting in caspase-3 activation contributing to apoptosis (Aires et al., 2007).  An apoptotic 
effect has also been shown for DHA in Hep2 human larynx tumour cells (Colquhoun, de Mello, 
& Curi, 1998), vascular smooth muscle cells from rats (Diep, Touyz, & Schiffrin, 2000; Diep et 
al., 2000) as well as human coronary artery smooth muscle cells (Feng et al., 2011) 
Pro-apoptotic effects have also been shown for several fatty acids including arachidonic 
acid (Artwohl et al., 2009; Pilane & Labelle, 2002), EPA (Finstad et al., 1998), and palmitate 
(Artwohl et al., 2009; deVries et al., 1997). A study using human smooth muscle cells incubated 
with stearic, oleic, linoleic, α-linolenic and arachidonic acid found that cells underwent apoptosis 
at a rate correlating with the fatty acids chain length and level of unsaturation. In this study, co-
incubation with caspase inhibitors decreased apoptosis to a level not significantly different than 
controls (Artwohl et al., 2009). The mechanism for this effect of fatty acids on apoptosis is 
unidentified. In addition to caspase 3 activation (Aires et al., 2007), some proposed mechanisms 
include activation of, p38 mitogen-activated protein kinase, cytochrome c, PPAR-α (Diep et al., 
2000; Diep et al., 2000).   
1.2.10 Negative Effects of Fish Oil 
Not all studies examining omega-3 HUFA and heart function have shown beneficial 
effects, with some studies indicating a proarrhythmic effect of fish oil. There appears to be a 
heterogeneous response to fish oil in patients with heart disease. The effects of fish oils on 
arrhythmias was examined in patients with implanted cardiac defibrillators in three double-blind, 
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randomized, placebo-controlled intervention studies (Brouwer et al., 2006; Leaf et al., 2005; Raitt 
et al., 2005). The results were varied, antiarrhythmic, proarrhythmic or no effect at all was found. 
The patients included in these trials had received an implantable defibrillator because of an 
existing ventricular tachycardia or ventricular fibrillation. This heterogeneous effect of fish oil 
might be explained by the mechanism of arrhythmia.  
There appears to be an association between the type of arrhythmia and the effect of fish 
oil. N3-HUFA appear to be protective against arrhythmias following healed infarction and heart 
failure (ex. GISSI trial), and inefficient in patients with acute ischemia (angina pectoris) (Coronel 
et al., 2007). Heart failure associated arrhythmias are based on triggered activity, in this situation 
decreased excitability is antiarrhythmic. Triggered activity occurs when an inward current occurs 
due to after-depolarizations that are large enough to reach the threshold potential for activation 
(Vermeulen et al., 1994). However, under conditions of re-entry as in myocardial ischemia, a 
decrease in myocardial excitability and action potential shortening, an effect that n-3-HUFA exert 
(Leaf et al., 2005), is proarrhythmic (Coronel et al., 2007).  
1.3 Methodological Foundations 
1.3.1 Investigation of Cardiac Metabolism 
Cardiac metabolism can be investigated in a variety of ways (see Table 3 for a summary 
of experimental models of ischemia). Whole animal in vivo studies are the most representative of 
heart function and metabolism, however, compensatory mechanisms and other confounding 
factors such as blood components and neurohormonal changes, prevent the isolation of individual 
aspects in this highly dynamic system. It is also difficult to control the environment of the heart 
and its substrates in situ which makes in vivo studies difficult and impractical. The use of 
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cultured cardiomyocytes is very common and is very useful for obtaining biochemical 
information; however, their application to the whole heart is restricted. Quiescent isolated cardiac 
myocytes do not represent the metabolic demand of the working heart and lack the cell to cell 
paracrine interactions that are critical to optimal functioning of the heart (Evans, Bennett, & 
Hauton, 2000). To avoid some of these issues, the ex vivo Langendorff heart preparation was 
developed.  
Table 3. Experimental models of ischemia. 
Cell culture models 
  Cells are raised under controlled experimental conditions 
 Ability to introduce pharmacological agents, cDNAs, antisense RNA and interfering 
peptides 
 Contractile function may be measured 
 Ability to induce transfection with certain genes 
In vivo 
  Most representative of heart function, the contribution of blood components and 
neurohormonal changes is considered. 
 Can make ECG, and hemodynamic parameter recordings 
 Possible to induce ischemia by coronary artery occlusion using a suture 
 Allows the examination of acute or chronic effects of ischemia 
 Many confounding factors may be involved 
Isolated perfused heart 
  Control of confounding factors such as; circulating neurohormonal factors and 
innervations 
 Heart rate can be paced to maintain a constant rhythm  
 Flow and pressures can be adjusted 
 Perfusate composition can be varied  
 Creating ischemia is easy 
 Contractility can be measured by using an intraventricular balloon 
 Can make ECG recordings 
 Can only investigate the acute effects on ischemia and reperfusion 
 
The isolated perfused heart was introduced by Oscar Langendorff more than a century ago 
and is now a predominant technique in pharmacological and physiological research. The 
technique allows the examination of cardiac contractile strength (inotropic effects), heart rate 
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(chronotropic effects) and vascular effects without the neuronal and hormonal complications of 
an intact animal model. The classical animals used for Langendorff preparations are small 
animals such as rats, rabbits, mice and guinea pigs. In the Langendorff preparation, the ascending 
aorta is cannulated and the heart is perfused in a retrograde fashion with constant flow or constant 
pressure. The perfusate is a buffered, nutrient rich, oxygenated solution (95%O2, 5%CO2). The 
perfusate commonly used is Krebs-Henseleit buffer which contains glucose and is kept at a 
constant temperature of 37°C and pH of 7.4.  The pressure of the solution causes the aortic valve 
to shut and the perfusate is then forced into the ostium and into the coronary vessels during 
diastole. This allows the heart to beat for several hours after its removal from the animal. If 
measurement of force is intended, a balloon for isovolumetric measurement of force is inserted 
via the left atrium into the cavity of the left ventricle. Isolated heart preparations are denervated, 
but beat within the physiological range spontaneously. Some parameters that can be obtained 
include heart rate, left ventricular pressure, end-diastolic pressure and the classical ECG 
parameters such as duration of QRS (Dhein, Michaelis, & Mohr, 2005). This preparation has 
several advantages including the ability to control and adjust perfusate composition, as well as 
the ability to induce conditions such as ischemia and hypoxia (Deleiris, Harding, & Pestre, 1984). 
It also allows the researcher to infuse pharmacological agents or any other substance for any 
precise amount of time and concentration. In doing this confounding factors such as absorption 
from the gastrointestinal system and blood and absorption by other tissues can be avoided 
compared to an in vivo model. 
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1.3.2 Fatty Acid Delivery Vehicles 
Fatty acids are insoluble in water and therefore require a delivery vehicle in an aqueous 
environment. There are several possible fatty acid delivery vehicles for physiological studies 
(Table 4).   
 
Table 4. Fatty acid delivery vehicles 
Vehicle Pro Con 
BSA 
  Commonly used in literature 
 Most physiological 
 Shown to have antioxidant properties 
(Brown et al., 1989) 
 Controversy regarding its delivery to cells 
 Trace amounts exert cardioprotective 
effects (maintains LVEDP to pre-ischemia 
values) (Watts & Maiorano, 1999) 
Ethanol 
  Easy and inexpensive  Exerts a cardioprotective effect against 
I/R injury. Appears to use the same 
signalling cascade as ischemic 
preconditioning (Chen, Gray, & Mochly-
Rosen, 1999) 
Dimethyl sulfoxide (DMSO) 
  Dissolves polar and nonpolar 
compounds and is highly miscible in 
water 
 Effect on inotropy and force generation of 
papillary muscles (Ogura, Kasamaki, & 
McDonald, 1996). Depressed contractile 
function of seen on diaphragm fibres by 
reversible dose-dependent inhibition of 
excitation contraction coupling (Reid & 
Moody, 1994).  
Methyl- β –cyclodextrin (MBCD) 
  Reported to extract less nutrients 
from cell and to deliver less impurities 
 FA dissociates from MBCD faster 
that from albumin 
 
 
 Disintegrates lipid rafts, which appear to 
be essential for ischemic preconditioning 
(0.2mM of MBCD abolished all 
cardioprotection by IPC) (Das et al., 2008). 
 The longer the chain the more that is 
needed. It is unknown how much would be 
required to complex this with DHA. 




Dimethyl sulfoxide (DMSO) and BSA have been used previously in isolated perfused 
heart models.  Methyl-β-cyclodextrin (MBCD) has not been used in an isolated perfused rat heart 
but has been utilized to deliver fatty acids to cells in transport studies (Brunaldi, Huang, & 
Hamilton, 2010). Initial pilot work indicated that ethanol is not an appropriate fatty acid delivery 
vehicle for this protocol as the ethanol and fatty acid mixture was not miscible with the buffer 
system at a low concentration of ethanol.  As such, palmitate precipitated out of solution upon 
mixture with the aqueous Krebs Bicarbonate buffer and the precipitate accumulated in the heart 
causing it to fail.   
In the literature, BSA is by far the most commonly used vehicle and represents the most 
physiological method (Table 5). A study to validate the use of BSA as a fatty acid delivery 
vehicle to an artificially perfused rat heart was conducted (see below). A concentration of 3% 
BSA was chosen based on an examination of the literature. No detectable differences in heart 
palmitate or DHA content were found compared to control hearts not receiving an infusion of 
BSA. In addition, the infusion of BSA had no effect on heart functional parameters including HR 
(p=0.88), LVEDP (p=0.17), rate of pressure development (p=0.11) or infarction size (p=0.63). 
These results indicated that 3% essentially fatty acid free BSA is an appropriate vehicle for fatty 
acid delivery to the artificially perfused rat heart. 
Table 5. Langendorff studies using 3% albumin complexed to fatty acids. 
BSA used Authors 
3% BSA with 1.2mM palmitate (Soltys et al., 2002) 
3% BSA with 1.2 mM palmitate (Grist, Wambolt, Bondy, English, & Allard, 2002) 
3% BSA with 1.2 mM palmitate (Lopaschuk et al., 1992) 
3% BSA with 1.2 mM palmitate (Davies, Lovlin, & Lopaschuk, 1992) 
3% BSA with 0.4 or 2.4mM palmitate (Ito et al., 2010) 
3% BSA with .4 or 2.4mM palmitate (Folmes, Sowah, Clanachan, & Lopaschuk, 2009) 





Rationale and Objectives 
2.1 Rationale 
There appears to be sufficient evidence indicating a protective role of DHA in ischemia 
reperfusion injury. Studies have used the Langendorff perfused heart model to examine heart 
parameters in the absence of neuronal, hormonal and blood complications (Zeghichi-Hamri et al., 
2010; Abdukeyum et al., 2008). However, these studies have used dietary protocols and therefore 
cannot conclusively determine the effect of n-3 HUFA on ischemia reperfusion injury. In dietary 
studies, the n-3 HUFA are incorporated into cellular membranes. One mechanism by which n-3 
HUFA exert their function on ion channels is as a free fatty acid upon release from phospholipids 
by phospholipases which are activated during ischemia.  The purpose of the present study is to 
examine the effect of DHA following 30 min of global no flow ischemia on heart function and 
infarction in the absence of previous n-3 HUFA phospholipid enrichment, and neuronal, blood, or 
hormonal complications. DHA will be infused immediately following ischemia to mimic the 
physiological infusion of n-3 HUFA caused by phospholipases. This will be paired with a similar 
dose response protocol for palmitate a reference saturated fatty acid.  
2.2 Statement of Objectives 
 The main objective of this thesis is to examine a dose response curve of DHA infused 
immediately following 30 minutes of global no flow ischemia on ischemia reperfusion injury as 
measured by area of infarction.  In addition, functional measurements of Left Ventricular End 
Diastolic Pressure (LVEDP, mmHg), Systolic (mmHg), Left Ventricular Developed Pressure 
(LVDevP, mmHg), Coronary Perfusuion Pressure (CPP) and the maximal Rate of Pressure 
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Development (+dP/dt, mmHg/s) will be made.  LVEDP is an indicator of contracture and 
LVDevP is a measure of contractility.  These results will be compared with a vehicle control and 
a fatty acid control consisting of the same infusion concentrations of palmitate.  In order to 
accomplish the main objective, several preliminary objectives were necessary to establish the 
model.  These included characterizing the fatty acid pools of the heart during the Langendorff 
procedure and developing a local technique to infuse specific fatty acids.  
2.3 Hypotheses 
The hypotheses of the present study are that; 
1. DHA infusion immediately following 30 minutes of global no flow ischemia will 
significantly reduce infarction area. 
2. Infusion of palmitate will neither significantly increase nor decrease the infarcted area.  
3. DHA infusion will reduce the increase in contracture seen during reperfusion, measured by 
left ventricular end diastolic pressure, and maintain left ventricular developed pressure, a 
measure of the hearts ability to contract.  







3.1 Langendorff Perfusion Procedure  
Prior to experimentation, rats are anesthetised intraperitoneally with sodium pentobarbital. 
Hearts are excised by first making a transverse incision in the abdominal cavity with scissors. 
The diaphragm is transected and lateral incisions are made along both sides of the rib cage. The 
anterior chest wall is folded back to reveal the heart and to remove the pericardium.  Next, fine 
tipped forceps grasp the ascending aorta as it is cut by scissors. The heart is lifted out of the 
thorax as remaining connective tissue and pericardium are removed and the heart is placed in ice-
cold Krebs Henseleit Buffer. The aorta is cannulated and perfused in a retrograde fashion with a 
modified Krebs-Henseleit bicarbonate buffer containing (in mmol/l) 118 NaCl, 4.7 KCl, 1.2 
KH2PO4, 1.2 MgSO4, 10 glucose, 2.5 CaCl2, and 2.5 NaHCO3, equilibrated with 95% O2-5% 
CO2 and warmed to 37° C at a pH of 7.4.  An equation which estimates in vivo flow rate from 
heart weight is used to set flow rate for this model; 
((((body weight (g)*0.0027)+0.6)^0.56)*7.43). 
Ventricular pressure is measured by a balloon catheter filled with degassed water 
(connected to a pressure transducer) and is adjusted to a mean left ventricular end-diastolic 
pressure (LVEDP) of approximately 5-10 mmHg during the initial equilibration. Perfusion 
pressure is also measured using a pressure transducer. Heart Rate (HR), Coronary perfusion 
pressure, Left Ventricular Developed Pressure, Left Ventricular End Diastolic and systolic (Sys) 
pressure, and rate of developed pressure are continuously recorded using PowerLab software. A 




3.2 Animals and Diets 
All animal procedures were approved by the University of Waterloo Animal Care 
Committee and were in accordance with the guidelines of the Canadian Council on Animal Care.  
Animal were housed in the animal housing facility of the Department of Kinesiology, University 
of Waterloo with temperature of 21 ± 1 °C and a reversed 12:12-h light-dark cycle.  Rats were 
fed a standard chow diet (Harlan, Teklad AIN-93G) (16) and had access to food and water ad 
libitum.  The fatty acid composition of the diet was confirmed by triplicate analyses in our 
laboratory (Table 6). 
Table 6. Fatty acid composition of Harlan Teklad 8640 rodent diet. 
Fatty Acid Diet Content (µg fatty acid/g of chow) 
16:0 5783 ± 447 
18:0 1523 ± 166 
Total saturated fatty acids 8058 ± 644 
16:1 315 ± 6 
18:1(n-7) 2938 ± 4 
18:1 n-9 9237 ± 2 
20:1(n-9) 134 ± 9 
Total monounsaturates 9611 ± 1198 
18:2(n-6) 21211 ± 1576 
20:4(n-6) 48 ± 7 
Total (n-6) polyunsaturates 21364 ± 1547 
18:3(n-3) 2511 ± 143 
20:5(n-3) 126 ± 1 
22:5(n-3) 27 ± 1 
22:6(n-3) 106 ± 7 
Total (n-3)  polyunsaturates 2769 ± 147 
Total Fatty Acids 42759 ± 3233 




3.3 Ischemia Reperfusion Protocol and Time Course 
A 30 minute normoxic period was used to allow the hearts to adjust to cannulation and to 
the intraventricular balloon. This normoxic period was sufficient time to achieve constant 
baseline left ventricular pressures. During this time, the balloon is inflated to the desired end 
diastolic pressure. This requires time to allow the degassed H2O to warm to the hearts 
temperature. The heart will then experience 30 minutes of ischemia. Ischemic arrhythmias are 
most pronounced in the first 15 minutes (McLennan et al. 1988). Pilot work found that 15 
minutes of global no flow ischemia was not severe enough to elicit an obvious amount of 
contracture and decreased contractility so the ischemia protocol was increased to 30 minutes of 
global no flow ischemia which has been used previously(Abdukeyum et al., 2008). Fifteen 
minutes of infusion was chosen to mimic previous research which infused varying concentrations 
of DHA to a Langendorff perfused heart without ischemia. This time was sufficient to allow the 
DHA to elicit electrophysiological changes to the hearts (Dhein et al., 2005). Seventy-five 
minutes of reperfusion was used to allow control hearts to return to baseline levels of ventricular 
pressures and to allow sufficient washout time of dehydrogenases for accurate infarct size 
staining (Schwarz, Somoano, Hale, & Kloner, 2000).   Hearts were excluded from the data if any 
of the exclusion criteria were met including a heart rate of less than 100 bpm or greater than 400 
bpm, or a left ventricular developed pressure of less than 65 mmHG. 
3.4 Functional Measurements of Recovery 
Heart function was evaluated by the recovery of left ventricular developed pressure 
(LVDevP, systolic – diastolic pressure), left ventricular systolic pressure (LVSysP) and left 
ventricular end diastolic pressure (LVEDP, a negative index of myocardial performance). 
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LVDevP is a measure of contractility which is decreased following ischemia. LVEDP is a 
measure of contracture which is elevated during ischemia and persists through reperfusion. In 
addition, the rate of developed pressure (+dP/dt mmHg/s), another measure of contractility which 
is decreased following ischemia, and coronary perfusion pressure (CPP), a measure of the 
pressure gradient between the aorta and the right atrium, were also measured continuously. 
3.5 Measurement of Ischemia 
Ischemic damage will be measured as the percentage of ischemic tissue in all heart tissue 
using triphenyltetrazolium chloride (TTC) staining. TTC stains viable tissue dark red as the 
tetrazolium salts react with the dehydrogenases in the cells and the infarcted tissue stains a pale-
white since they lack the enzymes with which the TTC reacts. Frozen tissue is sliced transversely 
into 1 mm slices, thawed and blotted dry. Fresh 1% w/v triphenyltetrazolium chloride (TTC) is 
made up in a phosphate buffer (88 mM Na2HPO4 , 1.8 mM NaH2PO4, pH=7.4) and poured over 
the heart slices. Heart slices are incubated for 10 minutes at 37°C for 10 minutes, agitated, then 
incubated for another 10 minutes. Slices are dabbed dry and imaged between 2 cover slides under 
a dissection microscope. A photograph is taken and the ischemic area in total heart area is 
digitally imaged using ImageJ software (NIH public domain, http://rsbweb.nih.gov/ij). The area of 
all hearts are summed together and converted to millimeters squared to get a ratio of total 
infarction area/ total area.  
3.6 Analysis of Fatty Acids 
Prior to lipid extraction, docosatrienoic acid (22:3 n-3) ethyl ester and 17:0 standards 
(Avanti Polar Lipids Inc, Alabaster, AL) were used as internal standards for total lipid extracts 
(TLEs), triacylglycerols (TGs), phospholipids (PLs), and non-esterified fatty acids (NEFA). 
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Lipids were extracted from hearts based on the method of Bligh and Dyer (Bligh & Dyer, 1959) 
via homogenization in methanol [containing 50μg/ml butylated hydroxyl toluene (BHT)] and 
subsequent addition of chloroform and sodium phosphate buffer (0.2 M, creating final solvent 
ratios of chloroform:methanol:phosphate buffer of 2:2:1.8), followed by collection of the organic 
phase. Total lipid extracts were stored at -80 °C until analysis.  
For fatty acid compositional analyses of individual lipids classes, total lipid extracts were 
applied to thin-layer chromatography (TLC) plates (20 x 20 cm) with a 60 Ǻ silica gel layer 
(Whatman Internation LTD, Maidstone, England) and placed in a resolving tank with reagents. 
The mobile phase reagents were heptane: diethyl ether: glacial acetic acid (60:40:2 v/v/v). Bands 
were visualized using 2,7-dicholroflourescein (Sigma-Aldich, Oakville, ON, Canada) under an 
ultraviolet lamp, and identified by comparison to a reference standard. Lipid classes of interest, 
triacylglycerols (TAG), nonesterified fatty acids (NEFA) and phospholipids (PL), were collected 
for transmethylation. 
The fatty acids in the total lipid extract and NEFA, TAG, and PL fractions were 
transesterified by heating at 85°C in 14% BF3 in methanol for 1 h (Morrison & Smith, 1964). The 
fatty acid methyl esters were collected and separated by fast gas chromatography using a Varian 
3900 gas chromatograph (Varian Inc, Mississauga, ON, Canada) with a DB-FFAP capillary 
column with 15 m × 0.10 mm inner diameter × 0.10 μm film thickness capillary column (J & W 
Scientific, Agilent Technologies, Palo Alto, CA). H2 was used as the carrier gas at a flow rate of 
30 ml/min. Chromatograms were analyzed by comparing to a reference standard (Nu-Check Prep 





Heart samples were homogenized in a lysis buffer containing .25M sucrose, .01M tris-
HCL, 0.01M MGCl2, 2.5mM DTT, and protease inhibitor (Roche Applied Science, Laval, QC, 
Canada). A bicinchoninic acid procedure was used to quantify protein content. 20 µg proteins 
were run on a 7.5-12.5% SDS-PAGE gel and transferred to a polyvinylidene fluoride membrane 
(Bio-Rad Laboritories, Misssissuga, ON). Membranes were blocked with 5% BSA or milk in 
TBS with 0.5% Tween (TBS-T) for 1 hour, incubated with primary antibody of the protein of 
interest, and washed with TBS-T. Membranes were then incubated for 1 hour with horseradish 
peroxidase-conjugated secondary (goat anti-rabbit or rabbit anti-goat, Santa Cruz Biotechnology) 
and washed with TBS-T. Chemiluminesence Western Blotting Detection Reagents (GE 
healthcare, PQ) were used for detection. Protein was visualized on a Chemigenius2 Bioimaging 
system (Syngene inc., Fredrick, MD). Molecular weights of proteins were confirmed using 
Precision Plus Protein WesternC Standards and Precision Protein Strep-Tactin HRP Conjugate 
(Bio-Rad Laboratories). Luminescence was normalized to controls and expressed as mean optical 
density in arbitrary units. To confirm equal protein loading and adequate transfer ponceau S stain 
(Bioshop, 148 Burlington, ON, Canada) was used. 
3.8 Fatty Acid Bovine Serum Albumin (BSA) Complex 
Fatty acid - BSA complexes were made fresh immediately prior to infusion and protected 
from light to mimic the free fatty acid or nonesterified fatty acid pool in plasma. DHA plasma 
levels have been reported to range from approximately 7µM to 80 µM DHA in humans (Newens, 
Thompson, Jackson, Wright, & Williams, 2011).  In n-3 PUFA deficient rat models, DHA can be 
undetectable and increase to 37 µM with fish meal based chow feeding (Bazinet, Rao, Chang, 
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Rapoport, & Lee, 2006). The appropriate amounts of fatty acids were dried down under nitrogen 
from an ethanol stock solution and 3% (w/v) essentially fatty acid free BSA (Sigma-Aldich, 
Oakville, ON, Canada) was added to achieve the required molarity.  The fatty acid – BSA 
mixtures were vortexed for 20 min for 3 cycles, with the tubes being checked between cycles to 
make sure the vortex equipment was not damaging them.  Immediately before infusion, the pH 
was raised to 7.4. Concentrations of DHA of 10, 20, 40, 60, 80, 100 and 120 µM DHA were 
chosen based on pilot work and equimolar concentrations of palmitate were repeated afterwards. 
Based on n=10 hearts, 100 µM of DHA is the highest concentration of DHA tolerated.  Four out 
of 6 hearts failed during the infusion of 120 µM DHA immediately following 30 min of global no 
flow ischemia due to fibrillation. In addition, no hearts were able to survive any concentration of 
DHA greater that 120 µM. 
3.9 Study Protocols 
3.9.1 Effect of Perfusion on Heart Fatty Acids and Fatty Acid Transport Proteins 
The effect of the Langendorff procedure on heart fatty acid pools and relevant fatty acid 
proteins were examined. Nine-week old female Sprague Dawley rats were sacrificed (n =12), 
heart tissue excised and then randomized to a baseline control (buffer rinse with no perfusion), 30 
min of perfusion and 4 h of perfusion in Langendorff mode with buffer as described above with 
no detectable fatty acids was used as the perfusate.  All hearts were immediately frozen for lipid 
and protein analysis upon excision (control) or after perfusion (30 min and 4 h groups).  Lipids 




3.9.2 Effects of Ischemia and BSA on Heart Fatty Acids and Heart Function 
Ten male Sprague Dawley rats approximately 10 weeks of age were used to evaluate the 
effects of BSA and ischemia on heart function and fatty acid content.  The rat hearts were 
randomized into 3 groups, an Ischemia group which was allowed to equilibrate for 30 min before 
being exposed to 30 min of global no flow ischemia followed by 1.5 h of reperfusion; a control 
group which was perfused for the same amount of time as the ischemia group but did not 
experience ischemia; and a BSA group which had 3% (w/v) essentially fatty acid free BSA added 
to the perfusion buffer for the last 15 minutes of the normoxic equilibration period before 30 
minutes of global no flow ischemia and 1.5 hrs of reperfusion at the original flow rate. All hearts 
were perfused in a retrograde fashion in Langendorff mode with the buffer described previously 
throughout the experiment, except during ischemia.  
3.9.3  The Effect of Post-ischemic Perfusion of DHA and Palmitate on Heart Function and 
Infarction 
For the main experiment of the project male Sprague Dawley (SD) rats 9 weeks of age 
were purchased from Harlan (Mississauga, ON, Canada) and housed in the animal housing 
facility of the Department of Kinesiology, University of Waterloo in a reversed 12:12-h light-
dark cycle and a temperature of 21 ±1 °C. All rats were allowed access to food and water ad-
libitum. All hearts were perfused in Langendorff mode for 30 min with buffer (described above). 
During this time the hearts were cleaned of extraneous tissue. All hearts experienced 30 minutes 
of global no-flow ischemia. Immediately following ischemia hearts were reperfused with KHB 
and an infusion of either 10, 20, 40, 60, 80, 100 or 120 µM of DHA or Palmitate complexed to 
3% (w/v) essentially fatty acid free BSA for 15 minutes. Control hearts received an infusion of 
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3% BSA alone in addition to the KHB. Hearts were then reperfused for an additional 75 minutes 
at the original flow rate in the absence of fatty acids (Figure 1). At the end of the protocol hearts 
were quickly removed and placed in ice cold KHB, and aorta and atrial tissue were removed. 
Hearts were dried, wrapped in plastic wrap and tinfoil and slowly frozen in -80°C where they 




Figure 1.  Langendorff protocol of ischemia reperfusion used in the present study. 
 
3.10 Statistics  
 Statistical analyses were performed using SPSS for windows version 19.0.  End point 
variables were compared using either independent t-tests (effect of BSA vehicle on heart fatty 
acids), 1-way ANOVA (perfusion time course on heart fatty acids and transport proteins), 2-way 
ANOVA (effect of dose and on infarction area) or 3-way ANOVA (effect of time, dose and 
infused fatty acid on heart functional variables). A priori comparisons between the fatty 
concentrations of DHA and palmitate with vehicle control, and between equimolar concentrations 
of DHA and palmitate were completed by independent t tests.  To protect against an increasing 
error rate, a two way ANOVA for fatty acid type and concentration was performed prior to 
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multiple comparisons (with significant F-value set at p<0.05) and the significance of a priori t 






4.1 Effect of Perfusion on Heart Fatty Acids and Fatty Acid Transport Proteins 
Total nonesterified fatty acid concentrations, were decreased (p<0.05) after 4 hours of 
perfusion relative to baseline control (Figure 2). Total fatty acids also decreased in the 
triacylglycerol fraction as well, but failed to reach statistical significance due to high variability 
in this pool (Figure 3).  The phospholipid fatty acid (Figure 4) and total lipid pool (Figure 5) 
remained relatively stable during perfusion. Immunoassays indicated that after 4hr perfusion, 
heart type fatty acid binding protein (H-FABP) was decreased (p=0.002), membrane associated 
fatty acid binding protein (FABPpm) was slightly but not significantly increased (p=0.09), and 
heart FAT/CD36 did not differ relative to baseline (P=0.27) (Figure 6).  
Figure 2. Fatty acid composition of the non-esterified fatty acid fraction of heart lipid extracts 
following artificial perfusion for 0 minutes, 30 minutes, and 4 hours. Data are expressed as means 
± SEM. MUFA, monounsaturated fatty acids; SFA, saturated fatty acids; n-6, omega 6 fatty 
acids; PUFA, polyunsaturated fatty acids. *p<0.05 compared to control. 
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Figure 3. Fatty acid composition of the triacylglycerol fraction of heart total lipids following 
artificial perfusion for 0 minutes, 30 minutes, and 4 hours. Data are expressed as means ± SEM. 
MUFA, monounsaturated fatty acids; SFA, saturated fatty acids; n-6, omega 6 fatty acids; PUFA, 
polyunsaturated fatty acids 
 
 
Figure 4. Fatty acid composition of the phospholipid fraction of heart total lipids following 
artificial perfusion for 0 minutes, 30 minutes, and 4 hours. Data are expressed as means ± SEM. 
MUFA, monounsaturated fatty acids; SFA, saturated fatty acids; n-6, omega 6 fatty acids; PUFA, 





Figure 5. Fatty acid composition of total lipids of heart total lipids following artificial perfusion 
for 0 minutes, 30 minutes, and 4 hours. Data are expressed as means ± SEM. MUFA, 
monounsaturated fatty acids; SFA, saturated fatty acids; n-6, omega 6 fatty acids; PUFA, 




Figure 6.  Heart protein expression of FABPpm, H-FABP, FAT/CD36 after 0 minutes, 30 
minutes, and 4 hours of artificial perfusion. Data are expressed as means ± SEM. * p<0.002 by 
independent samples t-test. (4hr vs. 0min).  
 
4.2 Effects of Ischemia and BSA on Heart Fatty Acids and Heart Function  
 Thirty minutes of global no flow ischemia and 1.5 hrs of reperfusion did not cause any 
significant decreases on heart total lipids (84.24±16.09 vs. 88.67±12.06 µM fatty acid), total 
TAGs (9.79 ± 7.12 vs. 7.65 ± 3.38 µM fatty acid), total PL (16.01 ± 1.55 vs. 15.58 ± 1.22 µM 
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fatty acid ), or total heart NEFA (0.37 ± 0.22 vs. 0.45 ± 0.12 µM fatty acid) compared to controls 
(Tables 7-10). 
The infusion of 3% BSA had more significant effects on heart fatty acid content. Heart 
total lipids did not decrease significantly compared to those hearts which received no BSA and 
were exposed to the same ischemia protocol (72.02 ± 6.82 vs. 84.24 ± 16.09 µM fatty acid). The 
most marked decreases caused by the infusion of BSA for 15 minutes prior to ischemia were seen 
in the dimethyl acetals (DMA). DMA are generated from plasmalogens during fatty acid 
extraction and derivitization to fatty acid methyl esters.  During acid mediated transesterification, 
the vinyl ether bond of fatty acids in plasmologens generates a doubly methylated fatty acid 
rather than the usual fatty acid methyl ester generated from typical acyl esters in triacylglycerols 
and phospholipids. Compared to the ischemia alone group, 16:0 DMA (1.08 ± 0.10 vs. 1.40 ± 
0.17 µM fatty acid), 18:0 DMA (0.54 ± 0.03 vs. 0.70 ± 0.06 µM fatty acid) and 18:1 DMA ( 0.35 
± 0.03 vs. 0.48 ± 0.03 µM fatty acid) all decreased significantly (p<0.05) in the total lipid 
fraction. Similarly, in the PL fraction 16:0 DMA (p=0.0002), 18:0 DMA (p=0.003) and 18:1 
DMA (p=0.002) were all decreased compared to the ischemia alone group (Table 7 and 8).  
There were no functional differences between BSA and KHB hearts at the end of infusion 
in HR, LVEDP, maximal rate of pressure development or infarction size. Additionally, BSA did 
not cause any significant differences in heart fatty acid content of DHA and palmitate which the 
following studies will be specifically examining. These results indicate that 3% essentially fatty 
acid free BSA is an appropriate fatty acid delivery vehicle for the infusion of fatty acid to an 













µM of fatty acid 
C 12:0   0.05 ± 0.05    0.05 ± 0.05   0.05 ± 0.05 
C 14:0   0.39 ± 0.04    0.35 ± 0.13   0.31 ± 0.09 
C 16:0 12.05 ± 1.56  12.09 ± 2.81   9.75 ± 0.19 
C 16:0 dma 1.50 ± 0.1    1.40 ± 0.17     1.08 ± 0.10* 
C 18:0 17.89 ± 2.43  16.13 ± 1.12 14.52 ± 1.34 
C 18:0 dma   0.70 ± 0.06    0.64 ± 0.03     0.54 ± 0.03* 
C 20:0   0.26 ± 0.03    0.26 ± 0.03   0.22 ± 0.03 
C 22:0   0.15 ± 0.03    0.18 ± 0.03   0.18 ± 0.03 
C 24:0   0.03 ± 0.03    0.03 ± 0.03   0.03 ± 0.03 
Total SFA 33.02 ± 4.33 31.13 ± 4.4 26.68 ± 1.89 
C 12:1 0.15 ± 0.05   0.20 ± 0.05   0.20 ± 0.05 
C 16:1 0.31 ± 0.08   0.35 ± 0.31   0.20 ± 0.08 
C 18:1 dma 0.48 ± 0.03   0.48 ± 0.06     0.35 ± 0.03* 
C 18:1n-7 3.79 ± 0.35   3.54 ± 0.53   3.26 ± 0.07 
C 18:1n-9 9.77 ± 0.46 10.09 ± 3.12   8.53 ± 1.49 
C 20:1n-9 0.68 ± 0.03   0.68 ± 0.13   0.61 ± 0.03 
C 22:1n-9 1.77 ± 0.35   2.22 ± 0.30   2.07 ± 0.09 
Total MUFA 16.95 ± 1.35 17.56 ± 4.50 15.22 ± 1.84 
C 18:2n-6 14.87 ± 2.64 14.94 ± 4.03 11.73 ± 0.68 
C 20:2n-6   0.19 ± 0.03   0.19 ± 0.03   0.16 ± 0.03 
C 20:3n-6   0.20 ± 0.03   0.16 ± 0.03   0.16 ± 0.03 
C 20:4n-6 15.08 ± 1.81 12.91 ± 1.41 12.02 ± 0.79 
C 22:4n-6   0.72 ± 0.12   0.63 ± 0.21   0.54 ± 0.12 
C 22:5n-6   0.64 ± 0.21   0.45 ± 0.21   0.27 ± 0.03 
Total N-6 31.70 ± 4.84 29.28 ± 5.92 24.88 ± 1.68 
C 18:3n-3   0.32 ± 0.07   0.40± 0.25   0.22 ± 0.11 
C 22:5n-3   0.21 ± 0.02   0.21 ± 0.02   0.18 ± 0.03 
C 22:6n-3   6.47 ± 1.45   5.66 ± 1.00   4.84 ± 1.27 
Total N-3  7.00 ± 1.54   6.27 ± 1.27   5.24 ± 1.41 
Total PUFA  45.7 ± 7.92 41.82 ± 8.46 35.36 ± 4.50 
Total fatty acids 88.67 ± 12.06   84.24 ± 16.09 72.02 ± 6.82 
dma, dimethyl acetal; SFA, saturated fatty acids; MUFA, monounsaturated fatty 
acids; PUFA, polyunsaturated fatty acids. Values are means ±SEM. *, 
Significantly different than Ischemia-Reperfusion matched controls (p<0.05) by 












µM fatty acid 
C 14:0   0.04 ± 0.04  0.04 ± 0.04  0.04 ± 0.04 
C 16:0   2.11 ± 0.08  2.18 ± 0.08  1.91 ± 0.16 
C 16:0 dma   0.28 ± 0.03  0.31 ± 0.03    0.17 ± 0.03* 
C 18:0   4.08 ± 0.18  4.08 ± 0.14  3.66 ± 0.35 
C 18:0 dma   0.13 ± 0.03  0.16 ± 0.03    0.10 ± 0.03* 
C 20:0   0.03 ± 0.03  0.03 ± 0.03  0.03 ± 0.03 
C 22:0   0.03 ± 0.03  0.03 ± 0.03  0.03 ± 0.03 
Total SFA   6.70 ± 0.42  6.83 ± 0.38  5.94 ± 0.67 
C 18:1 dma   0.10 ± 0.03  0.10 ± 0.03    0.06 ± 0.03* 
C 18:1n-7   0.53 ± 0.04  0.57 ± 0.04  0.53 ± 0.04 
C 18:1n-9   0.53 ± 0.07  0.50 ± 0.04  0.50 ± 0.07 
Total MUFA   1.16 ± 0.14  1.17 ± 0.11  1.09 ± 0.14 
C 18:2n-6   2.60 ± 0.18  2.82 ± 0.36  2.50 ± 0.53 
C 20:2n-6   0.03 ± 0.03  0.03 ± 0.03  0.03 ± 0.03 
C 20:3n-6   0.03 ± 0.03  0.03 ± 0.03  0.03 ± 0.03 
C 20:4n-6   3.32 ± 0.2  3.32 ± 0.30  3.12 ± 0.07 
C 22:4n-6   0.15 ± 0.03  0.15 ± 0.03  0.15 ± 0.03 
C 22:5n-6   0.15 ± 0.06  0.12 ± 0.06  0.06 ± 0.03 
Total N-6   6.28 ± 0.53  6.47 ± 0.81  5.89 ± 0.72 
C 18:3n-3   0.04 ± 0.04  0.04 ± 0.04  0.04 ± 0.04 
C 22:5n-3   0.04 ± 0.01  0.05 ± 0.01  0.04 ± 0.01 
C 22:6n-3   1.36 ± 0.09  1.45 ± 0.21  1.24 ± 0.30 
Total N-3   1.44 ± 0.13  1.54 ± 0.25  1.32 ± 0.35 
Total PUFA   7.72 ± 0.66  8.01 ± 1.06  7.21 ± 1.07 
Total FA 15.58 ± 1.22 16.01 ± 1.55 14.24 ± 1.88 
dma, dimethyl acetal; SFA, saturated fatty acids; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids. Values are means ±SEM. *, 
Significantly different than Ischemia-Reperfusion matched controls (p<0.001) 












µM fatty acid 
C 14:0 0.13 ± 0.04 0.13 ± 0.09 0.13 ± 0.09 
C 16:0 1.83 ± 0.62 2.26 ± 1.36 2.11 ± 1.05 
C 18:0 0.63 ± 0.07 0.70 ± 0.32 0.95 ± 0.46 
Total SFA 2.59 ± 0.73 3.09 ± 1.77 3.19 ± 1.60 
C 16:1 0.16 ± 0.08 0.16 ± 0.12 0.08 ± 0.08 
C 18:1n-7 0.21 ± 0.07 0.25 ± 0.18 0.25 ± 0.14 
C 18:1n-9 1.66 ± 0.92 2.09 ± 1.59 1.63 ± 1.17 
Total MUFA 2.03 ± 1.07 2.50 ± 1.89 1.96 ± 1.39 
C 18:2n-6 2.71 ± 1.35 3.71 ± 3.07 2.39 ± 1.57 
C 20:2n-6 0.03 ± 0.03 0.03 ± 0.03 0.03 ± 0.03 
C 22:5n-6 0.12 ± 0.06 0.21 ± 0.15 0.36 ± 0.21 
Total N-6 2.86 ± 1.44 3.95 ± 3.25 2.78 ± 1.81 
C 18:3n-3 0.14 ± 0.11 0.22 ± 0.18 0.11 ± 0.07 
C 22:6n-3 0.03 ± 0.03 0.03 ± 0.03 0.03 ± 0.03 
Total N-3 0.17 ± 0.14 0.25 ± 0.21 0.14 ± 0.10 
Total PUFA 3.03 ± 1.58 4.2 ± 3.46 2.92 ± 1.91 
Total FA 7.65 ± 3.38 9.79 ± 7.12 8.07 ± 4.90 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids. Values are means ±SEM. No significant 
differences were found. 
 








µM fatty acid 
C 18:0 0.25 ± 0.04 0.18 ± 0.07 0.21 ± 0.11 
Total SFA 0.41 ± 0.08 0.3 ± 0.11 0.37 ± 0.15 
C 18:1n-9 0.04 ± 0.04 0.07 ± 0.11 0.04 ± 0.04 
Total MUFA 0.04 ± 0.04 0.07 ± 0.11 0.04 ± 0.04 
Total FA 0.45 ± 0.12 0.37 ± 0.22 0.41 ± 0.19 
SFA, saturated fatty acids; MUFA, monounsaturated fatty acids; PUFA, 
polyunsaturated fatty acids. Values are means ±SEM. No significant 





4.3 The Effect of Post-ischemic Perfusion of DHA and Palmitate on Heart Function and 
Infarction 
4.3.1 Infarction Size 
Increasing concentrations of both palmitate and DHA caused increased infarction area in 
the hearts infused with fatty acids for 15 min immediately following 30 min of global no flow 
ischemia (Figure 7) and the interaction effect between the type of fatty acid and the 
concentration was significant (p=0.006).  Compared to controls which received an infusion of 
only 3% fatty acid free BSA, hearts receiving infusions of 80, 100 and 120 µM of DHA 
experienced significantly increased infarction (p<0.005) (Figure 7).  In fact, 120 µM of fatty acid 
was the maximum amount of DHA tolerated as several hearts (4/6) failed to complete the 
reperfusion protocol with the 120 µM infusion of DHA. Following a dramatic increase in 
contracture these hearts went into fibrillation and did not recover. In addition, hearts receiving 80, 
100 and 120 µM of palmitate experienced greater infarction than controls (p<0.025) (Figure 7). 
Both palmitate and DHA cause increasing infarction with increasing concentrations, however 
10µM of DHA caused significantly less infarction than 10µM of palmitate (p<0.025) (Figure 7). 
The infarction area after infusion with 10µM of DHA was also significantly lower than the 
vehicle control (p<0.025).  At infusion concentrations >10 µM, there was no differences in the 
infarction areas for equimolar concentrations of palmitate and DHA, although infarction area 


























































Figure 7. Myocardial Infarct Size. The effect of increasing concentrations of palmitate (Palm) 
and docosahexaenoic acid (DHA) on post ischemia and reperfusion infarct size (infarct 
volume/total heart volume). Valus are mean ± SEM. Two way ANOVA revealed a significant 
interaction (p=0.006). A priori comparisons between the fatty concentrations of DHA and 
palmitate with vehicle control, and between equimolar concentrations of DHA and palmitate 
were completed by independent t tests with significance set at p<0.025.  *Significantly different 
from vehicle control. #Significantly different from equimolar palmitate. 
 
 
4.3.2 Functional measurements 
Baseline functional measurements of heart rate, Left Ventricular End Diastolic Pressure, 
Left Ventricular Systolic Pressure, Left Ventricular Developed Pressure or maximal Rate of 
Pressure Development did not differ between groups after an analysis of variance (Table 11). For 
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each functional variable, dose responses over time are presented for each fatty acid and the 
difference between equimolar concentrations of palmitate and DHA were calculated and plotted 
to highlight the differences between the fatty acids. 
LVEDP rose gradually with ischemia and slowly returned to baseline in the control hearts 
(n=3).  The fatty acid dose and type interaction (p=0.004) and fatty acid dose and time interaction 
(p=0.014) were significantly different (Figures 8-10).  For both fatty acids, LVEDP tended to 
increase with the concentration, but the pressure gain was significantly greater with palmitate at 
60-100 µM.  In addition, with 80 and 100 µM infusions of palmitate, there was a dramatic and 
rapid increase in pressure during fatty acid infusion that then partially resolved with continued 
reperfusion.  Hearts receiving an infusion of 10 (n=3), 20 (n=3), and 40 (n=3) µM of DHA as 
well as 10 µM (n=4) of palmitate exhibited a very similar response as the controls. 
 Left Ventricular systolic pressure decreased with ischemia, and rapidly retuned to 
baseline levels with the onset of reperfusion and then tended to decline over the full course of 
reperfusion in the vehicle control hearts.  The fatty acid dose and type of fatty acid interaction 
(p<0.001) and fatty acid dose and time interaction (p=0.027) were significantly different (Figures 
11-13). All fatty acid infusions had a general response similar to control, but there did not appear 
to be a consistent pattern between concentration and pressure.  For example, for DHA infusions, 
10 and 100 µM infusions tended to have the lowest reperfusion pressures, while 20 and 40 µM 
infusions tended to have the highest reperfusion pressures and there were no concentration 
similarities to the palmitate responses. 
Left ventricular developed pressure (LVDevP) is a measure of contractility. A decreased 
pressure reflects an inability of the heart to exert pressure. LVDevP is normalized to each 
concentrations respective value to represent the percent change from baseline. The vehicle 
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control demonstrated a rapid and practically total decrease in pressure that rapidly increased with 
the start of reperfusion with a tendency to decline afterwards.  The fatty acid dose and type of 
fatty acid interaction (p<0.001), the fatty acid dose and time interaction (p=0.001) and the fatty 
acid type and time interaction (p=0.002) were all significantly different (Figures 14-16).  
Infusion of low concentrations of palmitate (10 and 20µM palmitate) tended to increase 
contractility as compared to higher concentrations (60 and 80 µM palmitate). Similarly to the 
hearts infused with palmitate, hearts infused with DHA exhibited increased LVDevP with lower 
concentrations (10 and 20 µM) as compared with higher concentrations of DHA (60, 80 and 100 
µM).  In addition, palmitate LVDevP tended to be higher for 10 and 20 µM and 80 and 100 µM, 
but similar for 40 and 60 µM as compared with DHA LVDevP. 
 Coronary perfusion pressure (CPP) is an indicator of the resistance in coronary arteries. 
The type of fatty acid and fatty acid dose interaction was significant (p<0.001) (Figures 17-19). 
In the vehicle control, ischemia caused a rapid decrease and slightly negative pressure, that was 
restored with and slightly increased during reperfusion.  During infusion with fatty acids, the 
increasing concentrations tended to result in increased pressure as reperfusion progressed with 
the highest concentration of each fatty acid causing the greatest CPP.  The higher doses of 
palmitate tended to causing higher pressures as compared with DHA. 
 Maximal rate of pressure development (+dP/dt) is normalized to baseline values to 
represent the percent change from baseline during reperfusion. Again, the vehicle control 
demonstrated a rapid and practically absolute decrease with ischemia, followed by a rapid 
increase with reperfusion and evidence of decline throughout the reperfusion.  The relative range 
of the rate response was large for the various fatty acid infusions.  The fatty acid dose X type of 
fatty acid X time interaction was significant (p<0.001) (Figures 20-22).  At the end of 
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reperfusion, +dP/dt was lower with the high concentrations of palmitate and DHA.  The infusion 
of 100 µM of palmitate or DHA resulted in 46% and a 52% decrease respectively from baseline 
values compared to a 21% decrease in controls (Figures 20 and 21).  The rate differences 
between DHA and palmitate were relatively similar for 40 µM.  The rate was generally lower for 
DHA infusions relative to palmitate except for 60 µM, where DHA was greater. 
 
Table 11. Heart baseline functional values. 
 LVEDP  LVSysP  LVDevP  + dP/dt  HR 
 mmHg mmHg/s bpm 
Control 
 7.8 ± 2.9 105 ± 16 97 ± 16 2446 ± 560 254 ± 21 
DHA µM 
10  9.5 ± 0.8 91 ± 16 81 ± 17 2063 ± 399 290 ± 26 
20 9.4 ± 3.1 115 ± 3 106 ± 4 2801 ± 618 256 ± 42 
40 7.5 ± 0.7 111 ± 3 104 ± 3 3600 ± 162 242 ± 23 
60 7.1 ± 1.0 121 ± 15 114 ± 15 3911 ± 530 309 ± 6 
80 7.0 ± 1.5 98 ± 14 91 ± 12 2358 ± 470 211 ± 35 
100 7.2 ± 1.3 99 ± 10 93 ± 9 2835 ± 364 288 ± 5 
Palmitate µM 
10 7.7 ± 1.1 139 ± 5 131 ± 4 3107 ± 363 224 ± 14 
20 16.3 ± 2.0 162 ± 28 146 ± 30 4614 ± 709 273 ± 40 
40 12.9 ± 1.1 157 ± 15 145 ± 16 5177 ± 448 308 ± 17 
60 9.0 ± 2.4 121 ± 18 112 ± 17 2765 ± 339 284 ± 15 
80 12 ± 3.8 161 ± 17 149 ± 19 5368 ± 722 293 ± 15 
100 9.7 ± 2.0 121 ± 17 111 ± 16 2784 ± 803 299 ± 6 
Heart Baseline Functional Values. LVEDP, Left Ventricular End Diastolic Pressure; LVSysP, 
Left Ventricular Systolic Pressure, LVDevP, Left Ventricular Developed Pressure; + dP/dt, 
maximal rate of pressure development; HR, Heart Rate. 
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Figure 8. Left Ventricular End Diastolic Pressure (LVEDP) 
and contracture curve during stabilization, ischemia, infusion 
and reperfusion of hearts receiving infusions of 10, 20, 40, 60, 
80 and 100 µM of palmitate (Palm). Values represent means ± 
S.E.M. 
 





































Figure 9. Left Ventricular End Diastolic Pressure (LVEDP) 
and contracture curve during stabilization, ischemia, infusion 
and reperfusion of hearts receiving infusions of10, 20, 40, 60, 
80 and 100 µM of docosahexaenoic acid (DHA). Values 
represent means ± S.E.M. 
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Figure 10. The average Left Ventricular End Diastolic Pressure (LVEDP) of hearts 
receiving an infusion of DHA subtracted by the average LVEDP of hearts receiving 
infusions of palmitate. Values represent means ± S.E.M. 
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Figure 11. Left Ventricular Systolic Pressure (LVSysP) curve 
during stabilization, ischemia, infusion and reperfusion of 
hearts receiving infusions of10, 20, 40, 60, 80 and 100 µM of 





















































Figure 12 Left Ventricular Systolic Pressure (LVSysP) curve 
during stabilization, ischemia, infusion and reperfusion of 
hearts receiving infusions of10, 20, 40, 60, 80 and 100 µM of 




































































Figure 13. The average Left Ventricular Systolic Pressure (LVSysP) of hearts receiving an 
infusion of DHA subtracted by the average LVSysP of hearts receiving infusions of 
palmitate. Values represent means ± S.E.M. 
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Figure 14 Left Ventricular developed pressure (LVDevP) of 
hearts infused with palmitate (Palm). LVDevP is the difference 
between systolic and diastolic pressure a measure of the hearts 
ability to contract. All data points are normalized to the 
respective baseline values. Values represent means ± S.E.M. 
 
 
Figure 15. Left Ventricular developed pressure (LVDevP) of 
hearts infused with docosahexaenoic acid (DHA). LVDevP is 
the difference between systolic and diastolic pressure a 
measure of the hearts ability to contract. All data points are 
normalized to the respective baseline values. Values represent 












































































Figure 16. The average Left Ventricular Developed Pressure (LVDevP) of hearts receiving 
an infusion of DHA subtracted by the average LVDevP of hearts receiving infusions of 
palmitate. Values represent means ± S.E.M. 
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Figure 17. Coronary Perfusion Pressure (CPP) curve during 
stabilization, ischemia, infusion and reperfusion of hearts 
receiving infusions of 10, 20, 40, 60, 80 and 100 µM of 
palmitate (Palm). Values represent means ± S.E.M. 
























































Figure 18. Coronary Perfusion Pressure (CPP) curve during 
stabilization, ischemia, infusion and reperfusion of hearts 
receiving infusions of 10, 20, 40, 60, 80 and 100 µM of 






































































Figure 19. The average Coronary Perfusion Pressure (CPP) of hearts receiving an infusion of 
DHA subtracted by the average CPP of hearts receiving infusions of palmitate. Values represent 
means ± S.E.M. 
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Figure 20. Maximal rate of pressure development (+dp/dt) of 
hearts receiving and infusion of palmitate (Palm). All data 
points are normalized to their respective baseline values. 
Values represent means±S.E.M
















































Figure 21. Maximal rate of pressure development (+dp/dt) of  
hearts receiving and infusion of docosahexaenoic acid (DHA). 
All data points are normalized to their respective baseline 


















































































Figure 22. The average maximal Rate of Pressure Development (+dP/dt) of hearts receiving and 
infusion of DHA subtracted by the average +dP/dt of hearts receiving infusions of palmitate. 






5.1 Comments on Hypotheses 
1. DHA infusion immediately following 30 minutes of global no flow ischemia will significantly 
reduce infarction area. 
 The infusion of DHA immediately following a bout of 30 min global no flow ischemia 
dose-dependently affects the infarct area in artificially perfused male Sprague Dawley rat hearts. 
The lowest concentration of DHA (10µM) delivered to the artificially perfused rat hearts 
significantly reduced the infarction area at the end of the reperfusion period. This was also 
significantly less than the infarction area of control hearts which only received an infusion of the 
fatty acid delivery vehicle 3% essentially fatty acid free bovine serum albumin  (p = 0.02 for both 
by LSD post hoc after significant F-value for 2-way ANOVA). However, this significant effect 
was not revealed using Tukey‟s Honest Significance test (p=0.46 and p=0.75 compared to 
equimolar palmitate and controls respectively). The infarct sizes after infusion of 20, 40 and 60 
µM for DHA were similar to controls. Infusions of 80, 100 and 120 µM of DHA, increased 
infarct sizes above that of controls and the lower dose fatty acid infusions. In fact after receiving 
infusions of 120 µM of DHA several hearts went into ventricular fibrillation which they could 
not recover from. 
2. Infusion of palmitate will neither significantly increase nor decrease the infarcted area.  
 Hearts infused with 80 and 120 µM of palmitate experienced greater infarction than 
controls. The finding that 120 µM of palmitate causes increased infarction compared to controls 
was not expected as pilot work using 1.2mM of palmitate (n=3), i.e. 10 times the molarity of the 
largest concentration used in the DHA infusion study, found no significant increases compared to 
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controls (n=2) (data not shown). However, this was based on a small number of hearts. It has 
been reported that palmitic acid (16:0) and stearic acid (18:0) induce apoptosis and alterations in 
the phospholipid membranes of neonatal rat ventricular myocytes that can be counteracted by the 
co-addition of equimolar amounts of monounsaturated fatty acids (deVries et al., 1997).  
 
3. DHA infusion will reduce the increase in contracture seen during reperfusion, measured by 
left ventricular end diastolic pressure, and maintain left ventricular developed pressure, a 
measure of the hearts ability to contract.  
Contrary to our hypothesis, the infusion of DHA 15 minutes immediately following 30 
minutes of global no flow ischemia caused an increase in Left Ventricular End Diastolic Pressure 
and contracture. Infusion of DHA also causes a decrease in Left Ventricular Developed Pressure 
and Rate of Pressure Development. This indicates that the hearts are no longer able to generate as 
much ventricular pressure.  
4. Infusion of palmitate will increase contracture and reduce left ventricular developed pressure. 
 As hypothesized, an acute infusion of palmitate increased the level of Left Ventricular 
End Diastolic Pressure and contracture and decreased the hearts ability to generate force as 





5.2 Effect of Perfusion on Heart Fatty Acids and Fatty Acid Transport Proteins 
Langendorff perfusion results in a decreased protein expression of the fatty acid transport 
protein H-FABP. This may be indicative of down regulation of fatty acid utilization as cellular 
fatty acid pools decreased. Artificial perfusion results in modest decreases in fatty acid 
concentrations in nonesterified and triacylglycerol fatty acid pools possibly as a result of fat 
oxidation. These changes may reflect the composition of the perfusate which contained no fatty 
acids which the heart prefers to oxidize. No effects on phospholipids or total lipid extracts were 
found. This makes the Langendorff heart an ideal model for the examination of the effects of 
fatty acid on a working heart. 
5.3 Effects of Ischemia and BSA on Heart Fatty Acids and Heart Function 
Thirty minutes of global no flow ischemia and 1.5 hrs of reperfusion did not cause any 
significant decreases in the concentration of heart total lipids, total triacylglycerols, total 
phospholipids, or heart total non-esterified fatty acids compared to controls. Although, 
phospholipase activity is dramatically increased during ischemia (Ford et al., 1991), the 
phospholipid pool is extremely large relative to circulating plasma free fatty acids pools. 
The infusion of 3% BSA had more significant effects on heart fatty acid content. Heart 
total lipids did not decrease significantly compared to those hearts which received no BSA and 
were exposed to the same ischemia protocol. The most marked decreases caused by the infusion 
of BSA for 15 minutes prior to ischemia were seen in the dimethyl acetals (DMA). Compared to 
the ischemia alone group 16:0 DMA, 18:0 DMA and 18:1 DMA all decreased significantly 
(p<0.05). Similarly, in the PL fraction 16:0 DMA, 18:0 DMA and 18:1 DMA were all decreased 
compared to the ischemia alone group (p<0.05). Early at the onset of global ischemia (2 minutes) 
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membrane-associated calcium-independent plasmalogen-selective phospholipase A2 activity has 
been shown to increase over 400%, to be nearly maximally activated after only 5 minutes, and to 
remain activated throughout the entire ischemic interval (2-60 minutes) (Ford et al., 1991). It is 
possible that during the long 1.5 hour of reperfusion the plasmologens, which were possibly 
hydrolyzed by phospholipases, were re-esterified back into plasmalogens since no decreases in 
DMA were seen following ischemia (Tables 7 and 8).  The infusion of BSA might have 
interfered with this by extracting the fatty acids prior to re-esterification, decreasing the levels of 
DMA. More studies would be required to elucidate this possible effect. 
Importantly, there were no effects caused by BSA on functional parameters including HR, 
LVEDP, Rate of Pressure Development or infarction size. There was also no effect on the fatty 
acid content of DHA or palmitate. These results validated the use of BSA in this model of fatty 
acid infusion. 
5.4 The Effect of Post-ischemic Infusion of DHA and Palmitate on Heart Function and 
Infarction 
The present study demonstrates that DHA as a free fatty acid has the potential to provide 
induce both beneficial and detrimental effects in the heart upon infusion during reperfusion post 
ischemia and that these effects are dose dependent.  At 10 µM DHA appears to exert a 
cardioprotective effect as indicated by reduced infarction size relative to vehicle and palmitate 
control.  This is physiologically relevant as DHA free fatty acid concentrations in plasma can be 
undetectable and increase to 37 µM in a fasting rat (Bazinet et al., 2006).  Intermediate infusion 
concentrations (20-60 µM) showed no benefits or detriments on infarction relative to control, 
while doses above 80 µM demonstrated increased infarction.  While the higher doses may not be 
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physiological for fasting animals, there is evidence that with feeding, postprandial levels of DHA 
can fall in this range in humans (Newens et al., 2011).  These results indicating a negative effect 
of DHA at high doses contradict other infusion studies (Billman et al., 1999; Kang & Leaf, 1994; 
Kang & Leaf, 1995; Kang & Leaf, 1996; Xiao et al., 2005; Xiao et al., 2008) and the hypothesis 
of this current study. The increased infarction area, increased contracture and decreased 
contractility caused by the infusion of varying levels of palmitate and DHA indicate a harmful 
effect on ischemia reperfusion injury, at least for this specific model of ischemia reperfusion. The 
negative effects observed with single treatment could be beneficial over chronic exposure 
through the preconditioning phenomenon, but further experimentation is needed.  However, it is 
clear that high DHA in the present model has negative effects as hearts infused with 120 µM of 
DHA went into fibrillation and failed.  The potential use of DHA infusion directly to the heart 
following ischemia in humans needs to be approached with caution as DHA. 
LVEDP is a measurement of contracture in the heart. Contracture, which is marked by a 
distinct rise in left ventricular end diastolic pressure, occurs by an absence of ATP and an 
overload of calcium in the myocyte causing actin-myosin crossbridges to remain in an attached 
state (Piper et al., 2003). The increased contracture caused by high levels of both palmitate and 
DHA are likely caused by excessive intracellular concentrations or possibly an inadequate 
amount of ATP available. It has been shown before that DHA can stimulates phospholipase C 
(PLC) which hydrolyzes the phosphatidylinositol 4,5-bisphosphate in membranes releasing free 
inositol trisphosphate (IP3) and diacylglycerol (DAG). Production of these second messengers 
results in a rapid release of Ca
2+
 from the endoplasmic reticulum causing an increase in 
intracellular calcium. This is possibly a contributing factor leading to the increase in contracture 
observed at high concentrations of DHA.  Increased calcium concentrations can also lead to ROS 
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production from the mitochondria and downstream signaling resulting in caspase-3 activation 
contributing to apoptosis (Aires et al., 2007). It is possible that the increase in infarction seen 
following DHA infusion may be caused by apoptosis. 
Previous studies using isolated perfused rat hearts have reported protective effects of n-3 
HUFA on infarction (Zeghichi-Hamri et al., 2010; Abdukeyum et al., 2008). These dietary 
studies differ from the present study in one important way. Dietary studies cannot differentiate 
between effects caused by increased n-3 HUFA or a decrease in other nutrients. These studies 
also cannot rule out the possibility that the fatty acids provided their benefit through interactions 
with other organs independent of the heart. In addition, in these studies the fatty acids are 
incorporated into heart phospholipids (Zeghichi-Hamri et al., 2010) and released by the increased 
activity of phospholipases during ischemia. Hearts in the present study did not experience the 
increase in DHA until the start of reperfusion (excluding endogenous release) which may have 
affected the influence of DHA on infarction.   
Rats consuming a normal chow diet as in this study still contain an adequate (for normal 
functioning) amount of DHA in their myocardial phospholipids. DHA is obtained through the 
minor amounts of preformed DHA in the chow as well as through biosynthesis of its dietary 
essential precursor alpha-linolenic acid (ALA; 18:3n-3). It is possible that with the endogenous 
infusion of DHA from phospholipids by phospholipases and the infusions of high concentrations 
of DHA in this study the cumulative amount that the heart and ion channels are experiencing is 
affecting the electrophysiology of cardiomyocytes in a negative way, while the lower 
concentrations infused are still within a beneficial range. Future studies should attempt to 
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quantify the amount of DHA released from phospholipids from rats on normal chow diets, as 
well as from rats consuming n-3 HUFA supplemented and deficient diets.  
5.5 Limitations 
A limitation of the artificially perfused heart model is that it does not actually represent a 
physiological environment. Circulating factors, hormonal and neural contributions which all 
affect ischemia reperfusion injury cannot play a role in this model. In addition, the acute infusion 
of DHA in this study is probably not an accurate representation of the physiological infusion 
during ischemia reperfusion. In a physiological setting, phospholipases release fatty acids during 
ischemia in addition to reperfusion. These lipases are also hydrolyzing other fatty acids from the 
sn-2 position such as arachidonic acid which would likely be playing a competitive role against 
n-3 HUFA.  Therefore, while the free fatty acid concentrations infused in the present study cover 
the physiological range for DHA, the relative range of 100% of the free fatty acids as DHA is not 
physiological. 
Also, palmitate was used as the fatty acid control.  Palmitate is a very abundant fatty acid 
in the circulation. It is relatively inexpensive and as such it was used for the model development.  
In the study, the infusion of palmitate caused a significant increase in infarction compared to 
controls. Palmitic acid (16:0) and stearic acid (18:0) induce apoptosis in neonatal rat ventricular 
myocytes and oleic acid (18:1n-9) has no affect on apoptosis (deVries et al., 1997). Oleic acid 
may be an inert control to use in the future.  In addition, AA should be considered as a 
physiological control as it tends to be the dominant HUFA in the sn-2 position of phospholipids, 
particularly when n-3 PUFA intake is low.   
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5.6 Future Directions 
Follow up studies should focus on quantifying apoptotic and necrotic cell death in this 
model of infusing fatty acids to an artificially perfused rat heart. This could be accomplished by 
examining the morphological features of apoptosis including; cell condensation and shrinkage, 
cell membrane blebbing, and cytoplasmic condensation or by examining the release of cytosolic 
proteins. In addition, it would also be valuable to examine any possible changes in the expression 
and activation of proteins involved in apoptotic signaling including but not limited to Bax, Bcl-2, 
p38 MAPK and Caspase-3. Measurements of intracellular calcium would assist in the 
understanding of the increased contracture caused by high levels of palmitate and DHA. 
In the future, an examination of other reference fatty acids may be relevant.  It has been 
shown that palmitic acid (16:0) and stearic acid (18:0) two saturated fatty acids induce apoptosis 
when directly applied to neonatal rat ventricular myocytes and that oleic acid (18:1n-9) has no 
affect on apoptosis (deVries et al., 1997). Oleic acid may be an inert control to use in the future. 
In addition, AA should be considered as a physiological control as it tends to be the dominant 
HUFA in the sn-2 position of phospholipids. 
5.7 Conclusion 
 The results of the present study indicate that the effects of an acute infusion of DHA 
immediately following 30 min of global no flow ischemia are dose dependent. The lowest 
concentration of DHA (10µM) delivered to the artificially perfused rat hearts significantly 
reduced the infarction area at the end of the reperfusion period. This was also significantly less 
than the infarction area of control hearts which only received an infusion of the fatty acid 
delivery vehicle 3% essentially fatty acid free bovine serum albumin.  Hearts receiving infusions 
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of 20, 40 and 60 µM of DHA or palmitate experienced similar areas of infarction as vehicle 
control.  The infusion of high concentrations of palmitate and DHA (80 and 100 µM) exacerbated 
ischemia reperfusion injury as demonstrated by an increase in infarction area, an increase in 
contracture and a decrease in the hearts ability to contract and generate force and infusion of 120 
µM of DHA tended to result in fibrillation and heart failure.  To be able to fully understand the 
mechanism of the protective effect of DHA on coronary heart disease and sudden cardiac death it 
is crucial to understand the dose response of DHA on the heart. In addition this dose response is 
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